

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/018962

International filing date: 14 June 2004 (14.06.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/478,210
Filing date: 13 June 2003 (13.06.2003)

Date of receipt at the International Bureau: 01 September 2004 (01.09.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



1215301

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

August 21, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/478,210

FILING DATE: June 13, 2003

RELATED PCT APPLICATION NUMBER: PCT/US04/18962

Certified by



Jon W Dudas

Acting Under Secretary of Commerce
for Intellectual Property
and Acting Director of the U.S.
Patent and Trademark Office

06-16-03

60478210 . 061303

PTO/SB/16 (05-03)

Approved for use through 4/30/2003. OMB 0851-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

Express Mail Label No. EV146603915US

INVENTOR(S)

Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
David B.	Weiner	Merion, Pennsylvania
Michele	Kutzler	Souderton, Pennsylvania
Andrew K.	Choo	Lansdale, Pennsylvania
Jean D	Boyer	Haddonfield, New Jersey

☐ Additional inventors are being named on the _____ separately numbered sheets attached hereto**TITLE OF THE INVENTION (500 characters max)****VACCINES AND IMMUNOTHERAPEUTICS USING IL-15 AND METHODS FOR USING THE SAME****CORRESPONDENCE ADDRESS**

Direct all correspondence to:

☒ Customer Number

34137

OR

Type Customer Number here

Place Customer Number
Bar Code Label here
34137
PATENT TRADEMARK OFFICE☐ Firm or
Individual Name

Address

Address

City

State

ZIP

Country

Telephone

Fax

ENCLOSED APPLICATION PARTS (check all that apply)☒ Specification Number of Pages

88

☐ CD(s), Number☒ Drawing(s) Number of Sheets

17

☐ Other (specify)☐ Application Data Sheet. See 37 CFR 1.76**METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT**☐ Applicant claims small entity status. See 37 CFR 1.27.☐ A check or money order is enclosed to cover the filing fees☒ The Director is hereby authorized to charge filing
fees or credit any overpayment to Deposit Account Number:

50-1275

FILING FEE
AMOUNT (\$)

\$160

☐ Payment by credit card. Form PTO-2038 is attached.

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.☐ Yes, the name of the U.S. Government agency and the Government contract number are: _____.

Respectfully submitted

SIGNATURE

Date

June 13, 2003

TYPED or PRINTED NAME

Mark DeLuca

REGISTRATION NO.
(if appropriate)

33,229

TELEPHONE

215-665-5592

Docket Number:

UPAP0020-001

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

17231 U.S. PTO
EV146603915US

17612 U.S. PTO

60/478210

06/13/03

UPAP0020-001

PATENT

**VACCINES AND IMMUNOTHERAPEUTICS USING IL-15
AND METHODS FOR USING THE SAME**

FIELD OF THE INVENTION

5 The present invention relates to improved vaccines, improved methods for prophylactically and/or therapeutically immunizing individuals against immunogens, and to improved immunotherapeutic compositions and improved immunotherapy methods.

BACKGROUND OF THE INVENTION

10 Immunotherapy refers to modulating a person's immune responses to impart a desirable therapeutic effect. Immunotherapeutics refer to those compositions which, when administered to an individual, modulate the individual's immune system sufficient to ultimately decrease symptoms which are associated with undesirable immune responses or to ultimately alleviate symptoms by increasing desirable immune responses. In some cases,
15 immunotherapy is part of a vaccination protocol in which the individual is administered a vaccine that exposes the individual to an immunogen against which the individual generates an immune response. In such cases, the immunotherapeutic increases the immune response and/or selectively enhances a portion of the immune response (such as the cellular arm or the humoral arm) which is desirable to treat or prevent the particular condition, infection or
20 disease.

UPAP0020-001

PATENT

Vaccines are useful to immunize individuals against target antigens such as allergens, pathogen antigens or antigens associated with cells involved in human diseases. Antigens associated with cells involved in human diseases include cancer-associated tumor antigens and antigens associated with cells involved in autoimmune diseases.

5 In designing such vaccines, it has been recognized that vaccines that produce the target antigen in cells of the vaccinated individual are effective in inducing the cellular arm of the immune system. Specifically, live attenuated vaccines, recombinant vaccines which use avirulent vectors, and DNA vaccines each lead to the production of antigens in the cell of the vaccinated individual which results in induction of the cellular arm of the immune
10 system. On the other hand, killed or inactivated vaccines, and sub-unit vaccines which comprise only proteins do not induce good cellular immune responses although they do induce a humoral response.

A cellular immune response is often necessary to provide protection against pathogen infection and to provide effective immune-mediated therapy for treatment of
15 pathogen infection, cancer or autoimmune diseases. Accordingly, vaccines that produce the target antigen in cells of the vaccinated individual such as live attenuated vaccines, recombinant vaccines that use avirulent vectors and DNA vaccines are often preferred.

While such vaccines are often effective to immunize individuals prophylactically or therapeutically against pathogen infection or human diseases, there is a
20 need for improved vaccines. There is a need for compositions and methods that produce an enhanced immune response.

UPAP0020-001

PATENT

Likewise, while some immunotherapeutics are useful to modulate immune response in a patient there remains a need for improved immunotherapeutic compositions and methods.

5 SUMMARY OF THE INVENTION

The present invention relates to recombinant vaccines that comprise a nucleic acid molecule that comprises a nucleic acid sequence that encodes an immunogen and a nucleic acid sequence that encodes a fusion protein that comprises a non-IL-15 signal sequence linked to IL-15 protein sequences and optionally, a nucleic acid sequence that encodes
10 CD40L; and to methods of immunizing an individual against an immunogen comprising administering to an individual such recombinant vaccines.

The present invention relates to live attenuated pathogens that comprise a nucleic acid molecule that comprises a nucleic acid sequence that encodes a fusion protein that comprises a non-IL-15 signal sequence linked to IL-15 protein sequences and optionally, a nucleic acid
15 sequence that encodes CD40L; to methods of immunizing an individual; and to methods of immunizing an individual against a pathogen comprising administering to an individual such live attenuated pathogens.

The present invention relates to isolated nucleic acid molecules that comprises nucleic acid sequence that encodes IL-15 protein and a nucleic acid sequence that encodes CD40L
20 protein, and optionally, a nucleic acid sequence that encodes an immunogen.

The present invention relates to compositions that comprise a nucleic acid molecule that comprises a nucleic acid sequence that encodes IL-15 protein and a nucleic acid

UPAP0020-001

PATENT

molecule that comprises a nucleic acid sequence that encodes CD40L protein, and optionally, on either or both nucleic acid molecules a nucleic acid sequence that encodes an immunogen.

The present invention relates to methods of modulating an immune response in an individual comprising administering to an individual a composition that comprises one or more nucleic acid molecules that comprise a nucleic acid sequence that IL-15 protein and a nucleic acid sequence that encodes CD40L. The various nucleic acid sequences that encode the various different proteins may be on the same nucleic acid molecule and/or different nucleic acid molecules or both.

The present invention relates to methods of inducing an immune response against an immunogen in an individual that comprises administering to an individual a composition that comprises one or more nucleic acid molecules that comprises a nucleic acid sequence that encodes IL-15 protein, and a nucleic acid sequence that encodes an immunogen and a nucleic acid sequence that encodes CD40L. The various nucleic acid sequences that encode the various different proteins may be on the same nucleic acid molecule and/or different nucleic acid molecules or combinations thereof.

The present invention relates to recombinant vaccines that comprise a nucleic acid molecule that comprises a nucleic acid sequence that encodes an immunogen, a nucleic acid sequence that encodes IL-15 protein, and a nucleic acid sequence that encodes CD40L; and to methods of immunizing an individual against an immunogen comprising administering to an individual such recombinant vaccines.

The present invention relates to live attenuated pathogens that comprise a nucleic acid molecule that comprises a nucleic acid sequence that encodes IL-15 protein and a nucleic

UPAP0020-001

PATENT

acid sequence that encodes CD40L; and to methods of immunizing an individual against a pathogen comprising administering to an individual such live attenuated pathogens.

BRIEF DESCRIPTION OF THE DRAWINGS

5 Figure 1 depicts data from Example 1 showing production of IFN- γ following stimulation of human PBMCs with IL-15 and monoclonal antibody to CD3. PBMCs were obtained from HIV-1 chronically infected subjects being treated with triple therapy (HAART). All donors' viral loads were below 500 copies/ml and their CD4 counts were above 500 cells/ml. To determine if IL-15 enhanced IFN- γ production as an indication of
10 effector function, the cells were stimulated with IL-15 and anti-CD3 and analyzed by a standard ELIspot assay.

 Figure 2 depicts data from Example 1 showing production of IFN- γ following stimulation of human PBMCs with IL-15 and monoclonal antibody to CD3 is predominantly CD8 mediated. PBMCs from HIV-1 chronically infected subjects being treated with triple
15 therapy (HAART) as described in Figure 1 were depleted of either CD4 or CD8 T cells and then stimulated with IL-15 and anti-CD3 and analyzed by a standard ELIspot assay.

 Figures 3A, 3B, 3C and 3D depict data from Example 1 showing antigen specific production of IFN- γ following stimulation of human PBMCs with HIV-1 peptides and IL-15. The PBMCs obtained from HIV-1 chronically infected subjects being treated with triple
20 therapy (HAART) were analyzed for their ability to secrete IFN- γ in response to 25 ng/ml of IL-15 (Figures 3A and 3C) and to HIV-1 Gag peptides in combination with IL-15 (Figures 3B and 3C) in a standard ELIspot assay. CD8 were depleted and the production of IFN- γ following stimulation with HIV-1 peptides and IL-5 was assessed as well (Figure 3D).

UPAP0020-001

PATENT

Figure 4, panels A, B and C depict data from Example 1 showing HIV-1 antigen specific cellular immune responses following immunization with HIV-1 DNA vaccine and IL-15. Balb/c mice were co-injected at weeks 0 and 2 with 50 µg of pCenv or pCgag with 50 µg of the pIL-15 an IL-15 expressing plasmid. Splenocytes were harvested two weeks post the final immunization. In Figures 4, panel A, the spleenocytes were tested by a standard Chromium release assay for CTL activity against HIV-1 envelope and recombinant vaccinia infected P815 cells. In Figure 4, panel B, the level of HIV-1 antigen specific chemokine secretion was analyzed. Splenocytes were stimulated with HIV-1 env recombinant vaccinia infected P815 cells. Supernatants were harvested on the third day and tested for secretion of MIP-1β. In Figure 4, panel C, the level of antigen specific secretion of IFN-gamma was assessed. Splenocytes were resuspended at a concentration of 5×10^6 cells/ml. A 100 µl aliquot was added to each well of a 96 well microtiter flat bottom plate. Recombinant p24 protein was added to wells in triplicate resulting in the final concentrations of 5 µg/ml and 1 µg/ml. The cells were incubated at 37°C in 5% CO₂ for three days and the supernatants harvested. The level of cytokine secreted were determine using commercially available ELISA kits.

Figure 5, panels A and B depict data from Example 1 showing intracellular staining for Th1 cytokines. Mice were given two injections with either pCgag alone or pCgag plus pIL-15 DNA plasmids. One week later, splenocytes were harvested and cultured *in vitro* for five hours in media containing a p55 peptide pool (containing 127 15mers spanning HIV-1 p55 with 11aa overlaps) and Brefeldin A. After stimulation, cells were stained extracellularly with anti-mouse CD3 and anti-mouse CD8 antibodies and then intracellularly with anti-

UPAP0020-001

PATENT

mouse. Figure 5, panel A, shows data for IFN- γ . Figure 5, panel B, shows data for Tumor Necrosis Factor- α . Dot plots display responses from CD3+/CD8+ lymphocytes.

Figure 6 depict data from Example 1 from murine T helper cell proliferation assays. Balb/c mice were co-injected at weeks 0 and 2 with 50 μ g of pCgag or pCenv and 50 μ g of the plasmids that express cDNAs of IL-2R-dependent Th1 cytokines IL-2 or IL-15. A 100 μ l aliquot containing 5×10^5 cells was immediately added to each well of a 96 well microtiter flat bottom plate. Recombinant p24 protein was added to wells in triplicate resulting in the final concentration of 5 μ g g/ml and 1 μ g g/ml. Stimulation Index was determined. Spontaneous count wells included 10% fetal calf serum, which serve as irrelevant protein control. Similarly, pCgag or control routinely have SI of 1 against their irrelevant gp 120 protein. To assure that cells are healthy, PHA or Con A (Sigma) was used as a polyclonal stimulator positive control.

Figure 7 depict data from Example 1 from epitope mapping of Gag in Balb/c mice following immunization with DNA vaccine pCgag. Balb/c mice were co-injected at weeks 0 and 2 with 50 μ g of pCgag and 50 μ g of the pIL-15 plasmid or with vector backbone that express genes IL-15 or vector backbone. Spleenocytes were isolated and set-up in a standard ELISPOT assay using a series of peptides. Peptides were mixed in a series of 22 pools in a matrix format and tested for their ability to activate cells to produce IFN- γ .

Figure 8, panels A, B and C depict data from Example 1 showing production of IFN- γ following stimulation of spleenocytes derived from CD4 knock-out mice. In Figure 8, panel A, Balb/c mice were co-injected at weeks 0 and 2 with 50 μ g of pCgag with 50 μ g of the pIL-15, an IL-15 expressing plasmid. Spleenocytes were harvested two weeks post the final immunization and tested for HIV-1 specific production of IFN- γ by ELISPOT. In Figure 8,

UPAP0020-001

PATENT

panel B, Cd4^{tm1K^{mw}} mice were immunized with pCgag with and without pIL-15. In Figure 8, panel C, Cd4^{tm1K^{mw}} mice were immunized with pCgag in combination with either, pIL-15, pCD40L or both. Splenocytes were harvested two weeks post the final immunization and assayed for HIV-1 Gag specific production of INF-gamma following *in vitro* stimulation with
5 HIV-1 Gag peptides.

Figure 9 depict data from Example 2 showing local production of IL-15 and CD40L at the vaccine site can replace the requirement for T cell help for expansion of CD8 effector T cells.

Figure 10, Figure 11, Figure 12 panels A-C, Figure 13 panels A-B, 14 and 15 refer to
10 the disclosure set forth in Example 3.

Figure 16 refers to data from the disclosure set forth in Example 4.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Definitions

15 As used herein the term "target protein" is meant to refer to peptides and protein encoded by gene constructs of the present invention that act as target proteins for an immune response. The terms "target protein" and "immunogen" are used interchangeably and refer to a protein against which an immune response can be elicited. The target protein is an immunogenic protein that shares at least an epitope with a protein from the pathogen or
20 undesirable cell-type such as a cancer cell or a cell involved in autoimmune disease against which an immune response is desired. The immune response directed against the target protein will protect the individual against and/or treat the individual for the specific infection or disease with which the target protein is associated.

UPAP0020-001

PATENT

As used herein, the term "genetic construct" refers to the DNA or RNA molecules that comprise a nucleotide sequence that encodes a target protein or immunomodulating protein. The coding sequence includes initiation and termination signals operably linked to regulatory elements including a promoter and polyadenylation signal capable of directing expression in
5 the cells of the individual to whom the nucleic acid molecule is administered.

As used herein, the term "expressible form" refers to gene constructs that contain the necessary regulatory elements operable linked to a coding sequence that encodes a target protein or an immunomodulating protein, such that when present in the cell of the individual, the coding sequence will be expressed.

10 As used herein, the term "sharing an epitope" refers to proteins that comprise at least one epitope that is identical to or substantially similar to an epitope of another protein.

As used herein, the term "substantially similar epitope" is meant to refer to an epitope that has a structure that is not identical to an epitope of a protein but nonetheless invokes a cellular or humoral immune response which cross reacts to that protein.

15 As used herein, the term "intracellular pathogen" is meant to refer to a virus or pathogenic organism that, at least part of its reproductive or life cycle, exists within a host cell and therein produces or causes to be produced, pathogen proteins.

As used herein, the term "hyperproliferative diseases" is meant to refer to those diseases and disorders characterized by hyperproliferation of cells.

20 As used herein, the term "hyperproliferative-associated protein" is meant to refer to proteins that are associated with a hyperproliferative disease.

As used herein the term "immunomodulating protein" refers to a protein that modulates the immune system of a person to whom the immunomodulating protein is

UPAP0020-001

PATENT

delivered. Examples of immunomodulatory proteins include: IL-15, CD40L, TRAIL; TRAIL_{recDRC5}, TRAIL-R2, TRAIL-R3, TRAIL-R4, RANK, RANK LIGAND, Ox40, Ox40 LIGAND, NKG2D, F46181 or MICA, MICB, NKG2A, NKG2B, NKG2C, NKG2E, NKG2F, CD30, CD153 (CD30L), Fos, c-jun, Sp-1, Ap1, Ap-2, p38, p65Rel, MyD88, IRAK, TRAF6, I κ B, NIK, SAP K, SAP1, JNK2, JNK1B2, JNK1B1, JNK2B2, JNK2B1, JNK1A2, JNK2A1, JNK3A1, JNK3A2, NF-kappa-B2, p49 splice form, NF-kappa-B2, p100 splice form, NF-kappa-B2, p105 splice form, NF-kappa-B 50K chain precursor, NFkB p50, human IL-1 α , human IL-2, human IL-4, murine IL-4, human IL-5, human IL-10, human IL-15, human IL-18, human TNF- α , human TNF- β , human interleukin 12, MadCAM-1, NGF IL-7, VEGF, TNF-R, Fas, CD40L, IL-4, CSF, G-CSF, GM-CSF, M-CSF, LFA-3, ICAM-3, ICAM-2, ICAM-1, PECAM, P150.95, Mac-1, LFA-1, CD34, RANTES, IL-8, MIP-1 α , E-selecton, CD2, MCP-1, L-selecton, P-selecton, FLT, Apo-1, Fas, TNFR-1, p55, WSL-1, DR3, TRAMP, Apo-3, AIR, LARD, NGRF, DR4(TRAIL), DR5, KILLER, TRAIL-R2, TRICK2, DR6, ICE, VLA-1, and CD86 (B7.2).

15 Overview

The invention arises from two discoveries: 1) fusion proteins that comprise IL-15 protein sequences linked to non-IL-15 signal peptide, particularly IgE signal peptide, are particularly useful in vaccines and in constructs for delivery of IL-15 protein as an immunomodulating protein; and 2) vaccines and immunomodulatory composition that involve delivery of IL-15 in combination with CD40L are particularly useful. In some preferred embodiments, the invention provides vectors, vaccines and immunomodulatory compositions and methods comprising nucleic acid molecules that comprise nucleotide sequences that encode proteins including fusion proteins in which the human IL-15 coding

UPAP0020-001

PATENT

sequences are provided free of IL-15 signal sequence, and more preferably free of the IL-15 Kozak region and untranslated regions. In some preferred embodiments, the invention provides vectors, vaccines and immunomodulatory compositions and methods comprising nucleic acid molecules that comprise nucleotide sequences that encode fusion proteins which
5 consist of: human IgE signal sequence linked to human IL-15 protein free of IL-15 signal sequence in combination with nucleotide sequences that encode human CD40L.

Fusion proteins comprising and genetic constructs encoding a non-IL-15 signal sequence linked to IL-15 protein

10 Another general aspect of the invention relates to fusion proteins comprising and genetic constructs encoding a non-IL-15 signal sequence linked to IL-15 protein and the use of such constructs in vaccines and immunomodulatory compositions. Several different embodiments and forms are provided with respect to this aspect. Generally, IL-15 refers to human IL-15. However, constructs can also refer to IL-15 from other species such as
15 canine, feline, equine, bovine, porcine or ovine for example.

This aspect of the invention arises from the observation that sequences in the protein expressed by the native IL-15 mRNA contain signals or elements which inhibit expression. By removing these inhibitory elements, improved expression is achieved. In preferred embodiments, the IL-15 coding sequence is free of the coding sequence for IL-15 signal
20 peptide, and preferably another signal protein such as IgE signal protein is provided in its place. Moreover, the IL-15 Kozak region and untranslated regions are removed as well to eliminate inhibitory elements. The only IL-15 sequences that constructs preferably include are the IL-15 sequences that encode the amino acid sequence of the mature IL-15 protein free of IL-15 signal peptide.

UPAP0020-001

PATENT

According to some embodiments, compositions are provided which comprise an isolated nucleic acid molecule comprising a nucleic acid sequence that encodes a fusion protein comprising a non-IL-15 signal sequence linked to IL-15 protein. In some preferred embodiments, a fusion protein consists of a non-IL-15 signal sequence linked to IL-15 protein. In some preferred embodiments, the IL-15 protein is free of IL-15 signal sequence. In some preferred embodiments, the fusion protein is non-immunogenic relative to the species from which the IL-15 sequences are derived. Thus a non-immunogenic fusion protein that comprises human IL-15 would be non-immunogenic in a human.

According to some embodiments, compositions are provided that include a construct which comprises coding sequences for a fusion protein comprising a non-IL-15 signal sequence linked to IL-15 protein may also include on the same nucleic acid molecule or a different nucleic acid molecule, a nucleic acid sequence that encodes an immunogen. Generally, immunogens, which are discussed below, may be any immunogenic protein including allergens, pathogen antigens, cancer-associated antigens or antigens linked to cells associated with autoimmune diseases. In preferred embodiments, the immunogen is a pathogen antigen, most preferably a pathogen selected from the group consisting of HIV, HSV, HCV, and WNV.

In preferred embodiments, the composition further comprises a nucleotide sequence that encodes CD40L. This nucleotide sequence may be included on the same nucleic acid molecule as the fusion protein or a different molecule. The CD40L may be included in vaccine compositions that include coding sequences for immunogens, yielding improved vaccines. In other embodiments, the CD40L may be included in immunomodulatory

UPAP0020-001

PATENT

compositions that do not include coding sequences for immunogens, yielding improved immunomodulatory compositions.

In some preferred embodiments, nucleic acid constructs are plasmids. In some preferred embodiments, the nucleic acid molecule is incorporated in a viral vector such as
5 vaccinia, adenovirus, adenovirus associated virus, retrovirus, or any other acceptable viral vector useful as a vaccine or gene therapy vector.

Genetic constructs comprising nucleotide sequences that encode a fusion protein comprising a non-IL-15 signal sequence linked to IL-15 protein may be incorporated directly into live attenuated pathogens according to some aspect of the invention. Examples of such
10 pathogens useful as vaccines are set out below. In preferred embodiments, human IL-15, preferably free of IL-15 signal sequence, is linked to human IgE signal sequence. In some embodiments, such attenuated pathogens are further provided with a nucleotide sequence that encodes CD40L.

A fusion protein that comprises a non-IL-15 signal sequence linked to IL-15 protein
15 sequence is an aspect of the invention. In some preferred embodiments, a fusion protein consists of a non-IL-15 signal sequence linked to IL-15 protein. In some preferred embodiments, the IL-15 protein is free of IL-15 signal sequence. In some preferred embodiments, the signal sequence is an IgE signal sequence. Sequences are preferably human. In some preferred embodiments, the fusion protein is non-immunogenic. Non-
20 immunogenic refers to the protein being non-immunogenic relative to the species from which the IL-15 sequences are derived.

Compositions comprising genetic constructs encoding IL-15 and CD40L and methods of using the same

UPAP0020-001

PATENT

Another general aspect of the invention relates to compositions comprising genetic constructs encoding IL-15 and CD40L and the use of such constructs in vaccines and immunomodulatory compositions. Several different embodiments and forms are provided with respect to this aspect. Generally, IL-15 refers to human IL-15. However, constructs can also refer to IL-15 from other species such as canine, feline, equine, bovine, porcine or ovine for example. The IL-15 may be in native form, i.e. with the IL-15 signal sequence. Preferably, the IL-15 is part of a fusion protein that includes a non-IL-15 signal sequence and most preferably is further free of IL-15 signal sequence. In preferred embodiments, the IL-15 is linked to an IgE signal sequence.

According to some embodiments, compositions are provided which comprise an isolated nucleic acid molecule comprising a nucleic acid sequence that encodes IL-15 and CD40L or two different isolated nucleic acid molecule including a first that comprises a nucleic acid sequence that encodes IL-15 and a second that comprises a nucleic acid sequence that encodes CD40L. In some preferred embodiments, the protein comprising IL-15 is non-immunogenic relative to the species from which the IL-15 sequences are derived.

According to some embodiments, compositions are provided that include a construct which comprises coding sequences for IL-15 and CD40L may also include on the same nucleic acid molecule or a different nucleic acid molecule, a nucleic acid sequence that encodes an immunogen. Generally, immunogens, which are discussed below, may be any immunogenic protein including allergens, pathogen antigens, cancer-associated antigens or antigens linked to cells associated with autoimmune diseases. In preferred embodiments, the immunogen is a pathogen antigen, most preferably a pathogen selected from the group consisting of HIV, HSV, HCV, and WNV.

UPAP0020-001

PATENT

Compositions that include coding sequences for immunogens are useful as vaccines. Compositions that do not include coding sequences for immunogens may be useful as immunomodulatory compositions. In some embodiments, protein immunogens, are also provided as a target for the immune response enhanced by the combination IL-15 and
5 CD40L.

In some preferred embodiments, nucleic acid constructs are plasmids. In some preferred embodiments, the nucleic acid molecule is incorporated in a viral vector such as vaccinia, adenovirus, adenovirus associated virus, retrovirus, or any other acceptable viral vector useful as a vaccine or gene therapy vector.

10 Genetic constructs comprising nucleotide sequences that encode IL-15 and CD40L may be incorporated directly into live attenuated pathogens according to some aspects of the invention. Examples of such pathogens useful as vaccines are set out below. In preferred embodiments, human IL-15, preferably free of IL-15 signal sequence, is linked to human IgE signal sequence

15 **Vaccines and immunomodulatory compositions**

According to some embodiments of the invention, compositions of the invention comprise genetic constructs including coding sequences for immunogens and/or immunogenic proteins. Such compositions are delivered to an individual to modulate the activity of the individual's immune system and thereby enhance the immune response against
20 the immunogen. When the nucleic acid molecules that encode an immunomodulatory protein are taken up by cells of the individual the nucleotide sequences that encode the immunomodulatory protein are expressed in the cells and the proteins are thereby delivered to the individual. Aspects of the invention provide methods of delivering the coding

UPAP0020-001

PATENT

sequences of the proteins on a single nucleic acid molecule, in compositions comprising different nucleic acid molecules that encodes one or more of the various transcription factor or intermediate factors, as part of recombinant vaccines and as part of attenuated vaccines.

According to some aspects of the present invention, compositions and methods are provided which prophylactically and/or therapeutically immunize an individual against a pathogen or abnormal, disease-related cells. The vaccine may be any type of vaccine such as, a live attenuated vaccine, a cell vaccine, a recombinant vaccine or a nucleic acid or DNA vaccine.

The present invention relates to compositions for delivering the immunomodulating proteins and methods of using the same.

The nucleic acid molecules may be delivered using any of several well known technologies including DNA injection (also referred to as DNA vaccination), recombinant vectors such as recombinant adenovirus, recombinant adenovirus associated virus and recombinant vaccinia.

DNA vaccines are described in US. Patent Nos. 5,593,972, 5,739,118, 5,817,637, 5,830,876, 5,962,428, 5,981,505, 5,580,859, 5,703,055, 5,676,594, and the priority applications cited therein, which are each incorporated herein by reference. In addition to the delivery protocols described in those applications, alternative methods of delivering DNA are described in US. Patent Nos. 4,945,050 and 5,036,006, which are both incorporated herein by reference.

Routes of administration include, but are not limited to, intramuscular, intranasally, intraperitoneal, intradermal, subcutaneous, intravenous, intraarterially, intraocularly and oral as well as topically, transdermally, by inhalation or suppository or to mucosal tissue such as

UPAP0020-001

PATENT

by lavage to vaginal, rectal, urethral, buccal and sublingual tissue. Preferred routes of administration include to mucosal tissue, intramuscular, intraperitoneal, intradermal and subcutaneous injection. Genetic constructs may be administered by means including, but not limited to, traditional syringes, needleless injection devices, or "microprojectile bombardment gene guns".

When taken up by a cell, the genetic construct(s) may remain present in the cell as a functioning extrachromosomal molecule and/or integrate into the cell's chromosomal DNA. DNA may be introduced into cells where it remains as separate genetic material in the form of a plasmid or plasmids. Alternatively, linear DNA that can integrate into the chromosome may be introduced into the cell. When introducing DNA into the cell, reagents that promote DNA integration into chromosomes may be added. DNA sequences that are useful to promote integration may also be included in the DNA molecule. Alternatively, RNA may be administered to the cell. It is also contemplated to provide the genetic construct as a linear minichromosome including a centromere, telomeres and an origin of replication. Gene constructs may remain part of the genetic material in attenuated live microorganisms or recombinant microbial vectors which live in cells. Gene constructs may be part of genomes of recombinant viral vaccines where the genetic material either integrates into the chromosome of the cell or remains extrachromosomal. Genetic constructs include regulatory elements necessary for gene expression of a nucleic acid molecule. The elements include: a promoter, an initiation codon, a stop codon, and a polyadenylation signal. In addition, enhancers are often required for gene expression of the sequence that encodes the target protein or the immunomodulating protein. It is necessary that these elements be operable

UPAP0020-001

PATENT

linked to the sequence that encodes the desired proteins and that the regulatory elements are operably in the individual to whom they are administered.

Initiation codons and stop codon are generally considered to be part of a nucleotide sequence that encodes the desired protein. However, it is necessary that these elements are functional in the individual to whom the gene construct is administered. The initiation and termination codons must be in frame with the coding sequence.

Promoters and polyadenylation signals used must be functional within the cells of the individual.

Examples of promoters useful to practice the present invention, especially in the production of a genetic vaccine for humans, include but are not limited to promoters from Simian Virus 40 (SV40), Mouse Mammary Tumor Virus (MMTV) promoter, Human Immunodeficiency Virus (MV) such as the HIV Long Terminal Repeat (LTR) promoter, Moloney virus, ALV, Cytomegalovirus (CMV) such as the CMV immediate early promoter, Epstein Barr Virus (EBV), Rous Sarcoma Virus (RSV) as well as promoters from human genes such as human Actin, human Myosin, human Hemoglobin, human muscle creatine and human metallothionein.

Examples of polyadenylation signals useful to practice the present invention, especially in the production of a genetic vaccine for humans, include but are not limited to SV40 polyadenylation signals and LTR polyadenylation signals. In particular, the SV40 polyadenylation signal that is in pCEP4 plasmid (Invitrogen, San Diego CA), referred to as the SV40 polyadenylation signal, is used.

In addition to the regulatory elements required for DNA expression, other elements may also be included in the DNA molecule. Such additional elements include enhancers. The

UPAP0020-001

PATENT

enhancer may be selected from the group including but not limited to: human Actin, human Myosin, human Hemoglobin, human muscle creatine and viral enhancers such as those from CMV, RSV and EBV.

Genetic constructs can be provided with mammalian origin of replication in order to
 5 maintain the construct extrachromosomally and produce multiple copies of the construct in the cell. Plasmids pVAX1, pCEP4 and pREP4 from Invitrogen (San Diego, CA) contain the Epstein Barr virus origin of replication and nuclear antigen EBNA-1 coding region which produces high copy episomal replication without integration.

In some preferred embodiments related to immunization applications, nucleic acid
 10 molecule(s) are delivered which include nucleotide sequences that encode a target protein, the immunomodulating protein and, additionally, genes for proteins which further enhance the immune response against such target proteins. Examples of such genes are those which encode other cytokines and lymphokines such as alpha-interferon, gamma-interferon, platelet derived growth factor (PDGF), TNF, GM-CSF, epidermal growth factor (EGF), IL- 1, IL-2,
 15 IL-4, IL-6, IL-10, IL-12 and IL- 15 including IL-15 having the signal sequence deleted and optionally including the signal sequence from IgE.

An additional element may be added which serves as a target for cell destruction if it is desirable to eliminate cells receiving the genetic construct for any reason. A herpes thymidine kinase (tk) gene in an expressible form can be included in the genetic construct.
 20 The drug gancyclovir can be administered to the individual and that drug will cause the selective killing of any cell producing tk, thus, providing the means for the selective destruction of cells with the genetic construct.

UPAP0020-001

PATENT

In order to maximize protein production, regulatory sequences may be selected which are well suited for gene expression in the cells the construct is administered into. Moreover, codons may be selected which are most efficiently transcribed in the cell. One having ordinary skill in the art can produce DNA constructs that are functional in the cells.

5 In some embodiments, gene constructs may be provided to in order to produce coding sequences for the immunomodulatory proteins described herein linked to IgE signal peptide. Such constructs and proteins are described in the application entitled "Expression vectors, vaccines and immunotherapeutics including modifications of the same and methods for using the same" filed on the same day as this application which names David B. Weiner, Michele
10 Kutzler, Andrew Choo and Joo-Sung Yang as co-inventors, which is incorporated herein by reference.

One method of the present invention comprises the steps of administering nucleic acid molecules intramuscularly, intranasally, intraperitoneally, subcutaneously, intradermally, or topically or by lavage to mucosal tissue selected from the group consisting of inhalation,
15 vaginal, rectal, urethral, buccal and sublingual.

In some embodiments, the nucleic acid molecule is delivered to the cells in conjunction with administration of a polynucleotide function enhancer or a genetic vaccine facilitator agent. Polynucleotide function enhancers are described in U.S. Serial Number 5,593,972, 5,962,428 and International Application Serial Number PCT/US94/00899 filed
20 January 26, 1994, which are each incorporated herein by reference. Genetic vaccine facilitator agents are described in US. Serial Number 021,579 filed April 1, 1994, which is incorporated herein by reference. The co-agents that are administered in conjunction with nucleic acid molecules may be administered as a mixture with the nucleic acid molecule or

UPAP0020-001

PATENT

administered separately simultaneously, before or after administration of nucleic acid molecules. In addition, other agents which may function transfecting agents and/or replicating agents and/or inflammatory agents and which may be co-administered with a GVF include growth factors, cytokines and lymphokines such as α -interferon, gamma-interferon, 5 GM-CSF, platelet derived growth factor (PDGF), TNF, epidermal growth factor (EGF), ILA, IL-2, IL-4, IL-6, IL-10, IL-12 and IL-15 as well as fibroblast growth factor, surface active agents such as immune-stimulating complexes (ISCOMS), Freund's incomplete adjuvant, LPS analog including monophosphoryl Lipid A (WL), muramyl peptides, quinone analogs and vesicles such as squalene and squalene, and hyaluronic acid may also be used administered in 10 conjunction with the genetic construct. In some embodiments, an immunomodulating protein may be used as a GVF. In some embodiments, the nucleic acid molecule is provided in association with PLG to enhance delivery/uptake.

The pharmaceutical compositions according to the present invention comprise about 1 nanogram to about 2000 micrograms of DNA. In some preferred embodiments, 15 pharmaceutical compositions according to the present invention comprise about 5 nanogram to about 1000 micrograms of DNA. In some preferred embodiments, the pharmaceutical compositions contain about 10 nanograms to about 800 micrograms of DNA. In some preferred embodiments, the pharmaceutical compositions contain about 0.1 to about 500 micrograms of DNA. In some preferred embodiments, the pharmaceutical compositions 20 contain about 1 to about 350 micrograms of DNA. In some preferred embodiments, the pharmaceutical compositions contain about 25 to about 250 micrograms of DNA. In some preferred embodiments, the pharmaceutical compositions contain about 100 to about 200 microgram DNA.

UPAP0020-001

PATENT

The pharmaceutical compositions according to the present invention are formulated according to the mode of administration to be used. In cases where pharmaceutical compositions are injectable pharmaceutical compositions, they are sterile, pyrogen free and particulate free. An isotonic formulation is preferably used. Generally, additives for isotonicity can include sodium chloride, dextrose, mannitol, sorbitol and lactose. In some cases, isotonic solutions such as phosphate buffered saline are preferred. Stabilizers include gelatin and albumin. In some embodiments, a vasoconstriction agent is added to the formulation.

According to some embodiments of the invention, methods of inducing immune responses against an immunogen are provided by delivering compositions of the invention to an individual. The vaccine may be a live attenuated vaccine, a cell vaccine, a recombinant vaccine or a nucleic acid or DNA vaccine.

In addition to using expressible forms of immunomodulating protein coding sequence to improve genetic vaccines, the present invention relates to improved attenuated live vaccines and improved vaccines that use recombinant vectors to deliver foreign genes that encode antigens. Examples of attenuated live vaccines and those using recombinant vectors to deliver foreign antigens are described in U.S. Patent Nos.: 4,722,848; 5,017,487; 5,077,044; 5,110,587; 5,112,749; 5,174,993; 5,223,424; 10 5,225,336; 5,240,703; 5,242,829; 5,294,441; 5,294,548; 5,310,668; 5,387,744; 5,389,368; 5,424,065; 5,451,499; 5,453,316; 5,462,734; 5,470,734; and 5,482,713, which are each incorporated herein by reference. Gene constructs are provided which include the nucleotide sequence that encodes an immunomodulating protein is operably linked to regulatory sequences that can function in the

UPAP0020-001

PATENT

vaccine to effect expression. The gene constructs are incorporated in the attenuated live vaccines and recombinant vaccines to produce improved vaccines according to the invention.

The present invention provides an improved method of immunizing individuals that comprises the step of delivering gene constructs to the cells of individuals as part of vaccine compositions which include are provided which include DNA vaccines, attenuated live vaccines and recombinant vaccines. The gene constructs comprise a nucleotide sequence that encodes an immunomodulating protein and that is operably linked to regulatory sequences that can function in the vaccine to effect expression. The improved vaccines result in an enhanced cellular immune response.

10 Immunogens

The present invention is useful to elicit enhanced immune responses against a target protein, i.e. proteins specifically associated with pathogens, allergens or the individual's own "abnormal" cells. The present invention is useful to immunize individuals against pathogenic agents and organisms such that an immune response against a pathogen protein provides protective immunity against the pathogen. The present invention is useful to combat hyperproliferative diseases and disorders such as cancer by eliciting an immune response against a target protein that is specifically associated with the hyperproliferative cells. The present invention is useful to combat autoimmune diseases and disorders by eliciting an immune response against a target protein that is specifically associated with cells involved in the autoimmune condition.

According to some aspects of the present invention, DNA or RNA that encodes a target protein and immunomodulating proteins is introduced into the cells of tissue of an individual where it is expressed, thus producing the encoded proteins. The DNA or RNA

UPAP0020-001

PATENT

sequences encoding the target protein and one or both immunomodulating proteins are linked to regulatory elements necessary for expression in the cells of the individual. Regulatory elements for DNA expression include a promoter and a polyadenylation signal. In addition, other elements, such as a Kozak region, may also be included in the genetic construct.

5 In some embodiments, expressible forms of sequences that encode the target protein and expressible forms of sequences that encode both immunomodulating proteins are found on the same nucleic acid molecule that is delivered to the individual.

In some embodiments, expressible forms of sequences that encode the target protein occur on a separate nucleic acid molecule from the nucleic acid molecules that contain
10 expressible forms of sequences that encode one or more immunomodulatory proteins. In some embodiments, expressible forms of sequences that encode the target protein and expressible forms of sequences that encode one or more of the immunomodulatory proteins occur on a one nucleic acid molecule that is separate from the nucleic acid molecule that contain expressible forms of sequences that encode one or more of the immunomodulating
15 proteins. Multiple different nucleic acid molecules can be produced and delivered according to the present invention and delivered to the individual. For example, in some embodiments, expressible forms of sequences that encode the target protein occur on separate nucleic acid molecule from the nucleic acid molecules that contain expressible forms of sequences that encode one or more of the two immunomodulating proteins which occur on separate nucleic
20 acid molecule from the nucleic acid molecules that contain expressible forms of sequences that encode one or more immunomodulating proteins. In such cases, all three molecules are delivered to the individual.

UPA0020-001

PATENT

The nucleic acid molecule(s) may be provided as plasmid DNA, the nucleic acid molecules of recombinant vectors or as part of the genetic material provided in an attenuated vaccine or cell vaccine. Alternatively, in some embodiments, the target protein and/or wither or both immunomodulating proteins maybe delivered as a protein in addition to the nucleic acid molecules that encode them or instead of the nucleic acid molecules which encode them.

Genetic constructs may comprise a nucleotide sequence that encodes a target protein or an immunomodulating protein operably linked to regulatory elements needed for gene expression. According to the invention, combinations of gone constructs that include one that comprises an expressible form of the nucleotide sequence that encodes a target protein and one that includes an expressible form of the nucleotide sequence that encodes an immunomodulating protein are provided. Incorporation into a living cell of the DNA or RNA molecule(s) that include the combination of gene constructs results in the expression of the DNA or RNA and production of the target protein and one or more immunomodulating proteins. An enhanced immune response against the target protein results.

The present invention may be used to immunize an individual against all pathogens such as viruses, prokaryote and pathogenic eukaryotic organisms such as unicellular pathogenic organisms and multicellular parasites. The present invention is particularly useful to immunize an individual against those pathogens which infect cells and which are not encapsulated such as viruses, and prokaryote such as gonorrhea, listeria and shigella. In addition, the present invention is also useful to immunize an individual against protozoan pathogens that include a stage in the life cycle where they are intracellular pathogens. Table 1 provides a listing of some o f the viral families and genera for which vaccines according to the present invention can be made. DNA constructs that comprise DNA sequences that

UPAP0020-001

PATENT

encode the peptides that comprise at least an epitope identical or substantially similar to an epitope displayed on a pathogen antigen such as those antigens listed on the tables are useful in vaccines. Moreover, the present invention is also useful to immunize an individual against other pathogens including prokaryotic and eukaryotic protozoan pathogens as well as
5 multicellular parasites such as those listed on Table 2.

In order to produce a genetic vaccine to protect against pathogen infection, genetic material that encodes immunogenic proteins against which a protective immune response can be mounted must be included in a genetic construct as the coding sequence for the target. Whether the pathogen infects intracellularly, for which the present invention is particularly
10 useful, or extracellularly, it is unlikely that all pathogen antigens will elicit a protective response. Because DNA and RNA are both relatively small and can be produced relatively easily, the present invention provides the additional advantage of allowing for vaccination with multiple pathogen antigens. The genetic construct used in the genetic vaccine can include genetic material that encodes many pathogen antigens. For example, several viral
15 genes may be included in a single construct thereby providing multiple targets.

Tables 1 and 2 include lists of some of the pathogenic agents and organisms for which genetic vaccines can be prepared to protect an individual from infection by them. In some preferred embodiments, the methods of immunizing an individual against a pathogen are directed against HIV, HSV, HCV, WNV or HBV.

20 Another aspect of the present invention provides a method of conferring a protective immune response against hyperproliferating cells that are characteristic in hyperproliferative diseases and to a method of treating individuals suffering from hyperproliferative diseases. Examples of hyperproliferative diseases include all forms of cancer and psoriasis.

UPAP0020-001

PATENT

It has been discovered that introduction of a genetic construct that includes a nucleotide sequence which encodes -an immunogenic "hyperproliferating cell"- associated protein into the cells of an individual results in the production of those proteins in the vaccinated cells of an individual. To immunize against hyperproliferative diseases, a genetic
5 construct that includes a nucleotide sequence that encodes a protein that is associated with a hyperproliferative disease is administered to an individual.

In order for the hyperproliferative-associated protein to be an effective immunogenic target, it must be a protein that is produced exclusively or at higher levels in hyperproliferative cells as compared to normal cells. Target antigens include such proteins,
10 fragments thereof and peptides; which comprise at least an epitope found on such proteins. In some cases, a hyperproliferative-associated protein is the product of a mutation of a gene that encodes a protein. The mutated gene encodes a protein that is nearly identical to the normal protein except it has a slightly different amino acid sequence which results in a different epitope not found on the normal protein. Such target proteins include those which are
15 proteins encoded by oncogenes such as *myb*, *myc*, *fyn*, and the translocation gene *bcr/abl*, *ras*, *src*, P53, *neu*, *trk* and EGRF. In addition to oncogene products as target antigens, target proteins for anti-cancer treatments and protective regimens include variable regions of antibodies made by B cell lymphomas and variable regions of T cell receptors of T cell lymphomas which, in some embodiments, are also used target antigens for autoimmune
20 disease. Other tumor-associated proteins can be used as target proteins such as proteins that are found at higher levels in tumor cells including the protein recognized by monoclonal antibody 17-IA and folate binding proteins or PSA.

UPAP0020-001

PATENT

While the present invention may be used to immunize an individual against one or more of several forms of cancer, the present invention is particularly useful to prophylactically immunize an individual who is predisposed to develop a particular cancer or who has had cancer and is therefore susceptible to a relapse. Developments in genetics and technology as well as epidemiology allow for the determination of probability and risk assessment for the development of cancer in individual. Using genetic screening and/or family health histories, it is possible to predict the probability a particular individual has for developing any one of several types of cancer.

Similarly, those individuals who have already developed cancer and who have been treated to remove the cancer or are otherwise in remission are particularly susceptible to relapse and reoccurrence. As part of a treatment regimen, such individuals can be immunized against the cancer that they have been diagnosed as having had in order to combat a recurrence. Thus, once it is known that an individual has had a type of cancer and is at risk of a relapse, they can be immunized in order to prepare their immune system to combat any future appearance of the cancer.

The present invention provides a method of treating individuals suffering from hyperproliferative diseases. In such methods, the introduction of genetic constructs serves as an immunotherapeutic, directing and promoting the immune system of the individual to combat hyperproliferative cells that produce the target protein.

The present invention provides a method of treating individuals suffering from autoimmune diseases and disorders by conferring a broad based protective immune response against targets that are associated with autoimmunity including cell receptors and cells which produce "self"-directed antibodies.

UPAP0020-001

PATENT

T cell mediated autoimmune diseases include Rheumatoid arthritis (RA), multiple sclerosis (MS), Sjogren's syndrome, sarcoidosis, insulin dependent diabetes mellitus (IDDM), autoimmune thyroiditis, reactive arthritis, ankylosing spondylitis, scleroderma, polymyositis, dermatomyositis, psoriasis, vasculitis, Wegener's granulomatosis, Crohn's disease and ulcerative colitis. Each of these diseases is characterized by T cell receptors that bind to endogenous antigens and initiate the inflammatory cascade associated with autoimmune diseases. Vaccination against the variable region of the T cells would elicit an immune response including CTLs to eliminate those T cells.

In RA, several specific variable regions of T cell receptors (TCRs) that are involved in the disease have been characterized. These TCRs include V β -3, V β -14, 20 V β -17 and Va-17. Thus, vaccination with a DNA construct that encodes at least one of these proteins will elicit an immune response that will target T cells involved in RA. See: Howell, M.D., *et al.*, 1991 *Proc. Nat. Acad. Sci. USA* 88:10921-10925; Piliard, X., *et al.*, 1991 *Science* 253:325-329; Williams, W.V., *et al.*, 1992 *J Clin. Invest.* 90:326-333; each of which is incorporated herein by reference. In MS, several specific variable regions of TCRs that are involved in the disease have been characterized. These TCRs include V β P and Va-10. Thus, vaccination with a DNA construct that encodes at least one of these proteins will elicit an immune response that will target T cells involved in MS. See: Wucherpfennig, K.W., *et al.*, 1990 *Science* 248:1016-1019; Oksenberg, J.R., *et al.*, 1990 *Nature* 345:344-346; each of which is incorporated herein by reference.

In scleroderma, several specific variable regions of TCRs that are involved in the disease have been characterized. These TCRs include V β -6, V β -8, V β -14 and Va-16, Va-3C, Va-7, Va-14, Va-15, Va-16, Va-28 and Va-12. Thus, vaccination with a DNA construct that

UPAP0020-001

PATENT

encodes at least one of these proteins will elicit an immune response that will target T cells involved in scleroderma.

In order to treat patients suffering from a T cell mediated autoimmune disease, particularly those for which the variable region of the TCR has yet to be characterized, a synovial biopsy can be performed. Samples of the T cells present can be taken and the variable region of those TCRs identified using standard techniques. Genetic vaccines can be prepared using this information.

B cell mediated autoimmune diseases include Lupus (SLE), Grave's disease, myasthenia gravis, autoimmune hemolytic anemia, autoimmune thrombocytopenia, asthma, cryoglobulinemia, primary biliary sclerosis and pernicious anemia. Each of these diseases is characterized by antibodies that bind to endogenous antigens and initiate the inflammatory cascade associated with autoimmune diseases. Vaccination against the variable region of antibodies would elicit an immune response including CTLs to eliminate those B cells that produce the antibody.

In order to treat patients suffering from a B cell mediated autoimmune disease, the variable region of the antibodies involved in the autoimmune activity must be identified. A biopsy can be performed and samples of the antibodies present at a site of inflammation can be taken. The variable region of those antibodies can be identified using standard techniques. Genetic vaccines can be prepared using this information.

In the case of SLE, one antigen is believed to be DNA. Thus, in patients to be immunized against SLE, their sera can be screened for anti-DNA antibodies and a vaccine can be prepared which includes DNA constructs that encode the variable region of such anti-DNA antibodies found in the sera.

UPAP0020-001

PATENT

Common structural features among the variable regions of both TCRs and antibodies are well known. The DNA sequence encoding a particular TCR or antibody can generally be found following well known methods such as those described in Kabat, *et al 1987 Sequence of Proteins of Immunological Interest* U.S. Department of Health and Human Services, Bethesda MD, which is incorporated herein by reference. In addition, a general method for cloning functional variable regions from antibodies can be found in Chaudhary, V.K., *et al*, 1990 *Proc. Natl. Acad. Sci. USA* 87:1066, which is incorporated herein by reference.

EXAMPLES

10 Example 1

INTRODUCTION

The success of combination antiretroviral therapy, to reduce viral load in infected subjects resulted in improved prognosis for many HIV-1 positive individuals. However, a number of laboratories have reported that the established viral reservoir is poorly impacted by combination drug regimens (References 1-3 below). To date no combination therapy approach has resulted in viral clearance and there are significant side effects associated with current therapeutic regimens that ultimately affect patient compliance and impact disease course. Therefore, there is a great need to explore alternative forms of therapy including potential immunotherapeutic approaches for HIV-1. It is believed CD8+ T cell responses are important for controlling HIV-1 infection and in slowing disease progression. Although the exact function of HIV-1 specific CD8+ T cell responses in controlling viral replication has not been completely elucidated, a correlation has been established between long term non-progression in individuals seropositive for HIV-1 and specific CD8+ T cell-mediated cellular

UPAP0020-001

PATENT

responses (References 4-7 below). In addition, a cohort of highly exposed, but HIV negative individuals in Gambia have not demonstrated antibody responses, yet have shown anti-HIV-1 CD8+ T cell immune responses (References 8 and 9 below). Indeed, following HIV-1 infection a robust cellular immune response is induced with a concurrent drop in viral load.

5 Yet, despite the presence of high levels of HIV specific cytotoxic T lymphocytes (CTL), HIV-1 infection is not cleared. This discrepancy between a high CD8 mediated response and continued disease progression is of concern. The inability of the CTLs to clear virus may be due in part to the CTL escape mutants (References 10-14 below), possibly immunopathogenesis of the virus, such as Nef-associated down-regulation of MHC class I or

10 Vpr or Env effects on the host immunity (References 15-18 below). An additional issue is the lack of effective CD4+ T cell help for CD8+ T lymphocytes (References 19 and 20 below). It has been observed that circulating CD8+ cells may have impaired function (Reference 21 below). If HIV-1 immunopathogenesis limits development of an effective CD8 response, then presentation of HIV-1 antigens in the context of anti-retroviral therapy

15 could boost CD8 memory and effector cells in a limited fashion. These events could have a potential impact on disease outcome. However, it may be important to provide help for CD8+ T cell expansion. In this regard, the survival of CD8+ memory T cells was found not to be contingent on continued antigen presentation, (Reference 22 below) but it might rather be dependent on production of specific cytokines in the peripheral environment.

20 One such cytokine that appears to significantly impact CD8+ T cells is interleukin-15 (IL-15). Waldmann and colleagues first reported that IL-15 is a 15 kDa protein that uses the gamma and beta chains of the IL-2 receptor complex in concert with a unique alpha chain to signal T cells (Reference 23 below). IL-15 manifests anti-apoptotic activity and appears to

UPAP0020-001

PATENT

play a role in stimulating a memory CD8+ T cell phenotype. The role IL-15 plays in HIV-1 infection is being investigated by a number of groups. IL-15 has been demonstrated to reduce apoptosis of lymphocytes isolated from HIV-1 infected subjects (Reference 24 below) and increase activity and proliferation of natural killer cells, (References 25-27 below). IL-15 has also been implicated in B cell proliferation (References 28 and 29 below) of HIV-1 infected subjects and activation of macrophages (Reference 30 below). Importantly, IL-15 also appears to have a direct role on the HIV-1 effector T cell proliferation and interferon-gamma (IFN-gamma) production (References 31 and 32 below). Yet, IL-15, was not able to stimulate IFN-gamma in many subjects tested who were seropositive for HIV-1. The effects of IL-15 on antigen specific CD8 + T cellular immune responses were therefore explored.

The effects of IL-15 on T cells isolated from chronically infected HIV-1 seropositive subjects were examined. It was found that rhIL-15 enhances proliferation of CD8 T cells, and importantly, IL-15 expanded effector antigen specific CD8+ IFN-gamma production in all subjects. In an immunization model IL-15 boosted CD8+ effector function, which was explored in an immunization model system. CD8+ lymphocytes from mice were able to lyse targets expressing HIV-1 antigens at a higher level when IL-15 was provided *in trans*. This effect occurred in the absence of strong proliferation of CD4+ T cell. However, in CD4 knockout (KO) mice IL-15 could not completely by-pass the requirement for CD4 help in the generation of the CD8 effector response. These results suggest that IL-15 is highly effective at expansion of CD8 memory cells but IL-15 alone is not sufficient for their initial generation.

MATERIALS AND METHODS

ELISpot assay on Human PBMCs

UPAP0020-001

PATENT

PBMCs isolated from HIV-1 positive volunteers by basic ficoll-hypaque technique were assessed for effector function by a standard ELISPOT assay. PBMCs were resuspended in RPMI with 10% FCS (R10) at a concentration of 1×10^6 cells/ml. The antibody 1-DIK (Mabtech, Mariemont OH; Nacka, SE) was diluted to 15 $\mu\text{g/ml}$ in 0.1 M carbonate-bicarbonate solution (pH 9.6) and used to coat 96-well nitrocellulose membrane plates (Millipore, Bedford, MA). The plates were incubated at 4°C overnight. Plates were washed 6 times with 200 μl of PBS. A mixture of 122 sterile peptides was prepared as a cocktail at a concentration (for each peptide) of $50\mu\text{g}/\mu\text{l}$ in DMSO. The peptides are a series of overlapping peptides, 15 amino acids in length, that encompass all of HIV-1 Gag (AIDS Reagent and Reference Repository, ARRR). 100,000 PBMCs were added to each well (100 μl @ 1.0×10^6 cells/ml) of the nitrocellulose antibody-coated plates, along with 100 μl of the peptide cocktail diluted 1:200 in R10 with or without 50 ng/ml IL-15 (final concentration 25 ng/ml). Each sample was assayed in triplicate. PHA at 5 $\mu\text{g/ml}$ was used as a positive control. The plates were incubated at 37°C for approximately 24 hours. The plates were then washed 6 times with 200 μl of PBS. 100 μl of antibody 7-B6-1-Biotin (Mabtech) was added to each well at a concentration of $1\mu\text{g/ml}$ in PBS. Plates were incubated at room temperature for 2-4 hours. The plates were washed 6 times with 200 μl of PBS. 100 μl of Streptavidin-ALP (Mabtech) was added to each well at a concentration of $1\mu\text{g/ml}$ in PBS. The plates were incubated at room temperature for 1-2 hours. The plates were washed 6 times with 200 μl of PBS. 100 μl of substrate solution (BCIP/NBT, Sigma) was added to each well. The developing solution was removed with tap water. Dynabeads (Dynal Biotech, Lake success, NY; Oslo, NO) coupled to monoclonal antibody specific for either CD8 or CD4 were used to deplete CD8 and CD4 populations.

UPAP0020-001

PATENT

Co-stimulation of PBMCs with monoclonal antibody to CD3

Isolated PBMCs from subjects seropositive for HIV-1 were stimulated with monoclonal antibody specific for CD3 bound to Dynabeads (DynaL Biotech) with or without IL-15 (50 ng/ml) and analyzed for production of IFN-gamma by ELISPOT as described
5 above. Dynabeads (DynaL Biotech) coupled to monoclonal antibody specific for either CD8 or CD4 were used to deplete CD8 and CD4 populations.

Co-stimulation of PBMCs with CD40L

CD40L protein was tested in combination with IL-15 and the peptide mix at a concentration of 250 µg/ml and analyzed for production of IFN-gamma by ELISPOT as
10 described above

Plasmid immunization in mice

Female Balb/c mice were co-vaccinated at weeks 0 and 2 with 50 µg of pCgag or pCenv and 50 µg of the plasmids that express genes of IL-2R-dependent Th1 cytokine IL-15 as previously described (Reference 33 below). Mice homozygous for the $Cd4^{tm1Kw}$ targeted
15 mutation were also used. These mice have a complete block in $CD4^+$ T-cell development due to a mutation in the CD4 gene; 90% of their circulating T-cells are $CD8^+$. Homozygous mutant mice also show a Class II restricted deficit in helper T-cell activity and other T-cell responses. B6.129S6- $Cd4^{tm1Kw}$ were co-vaccinated at weeks 0 and 2 with 50 µg of pCgag and 50 µg of the plasmids that expresses CD40L, IL-15 or both in combination. All DNA was
20 made using Qiagen columns and final formulations were 0.25% bupivacaine in isotonic citrate buffer. Splens were harvested one week post the second injection.

Murine cytotoxic T lymphocyte assay

The CTL response was assessed in a five hour ^{51}Cr release CTL assay using recombinant vaccinia infected cells as targets. Splenocytes were isolated one week following

UPAP0020-001

PATENT

vaccination and stimulated *in vitro*. The effectors were stimulated with relevant vaccinia-infected cells. P815 were infected with vDK1 for gag/pol, (ARRR) or vMN462 (ARRR) for env. The stimulators were fixed with 0.1% glutaraldehyde as previously described and incubated with the splenocytes at a ratio of 1:20 for four to five days in CTL culture media.

- 5 CTL culture media consisted of 1:1 ratio of Iscove's Modified Dulbecco Media (Gibco-BRL, Grand Island, NY) and Hanks' Balanced Salt Solution (Gibco-BRL) with 10% fetal calf serum 1640 (Gibco-BRL) and 10% RAT-T-STIM without Con A (Becton Dickinson Labware, Bedford, MA). Vaccinia-infected targets were prepared by infecting 3×10^6 P815 cells at a multiplicity of infection (MOI) of 10 for twelve hours at 37°C. A standard
- 10 Chromium release assay was performed in which the target cells were labeled with 20 $\mu\text{Ci/ml}$ $\text{Na}_2^{51}\text{CrO}_4$ for 120 minutes and incubated with the stimulated effector splenocytes for six hours at 37°C. CTL lysis was determined at effector: target (E:T) ratios ranging from 50:1 to 12.5:1. Supernatants were harvested and counted on a LKB CliniGamma gamma-counter. Percent specific lysis is determined from the formula:

15

$$100 \times \frac{\{\text{experimental release} - \text{spontaneous release}\}}{\text{maximum release} - \text{spontaneous release}}$$

- Maximum release was determined by lysis of target cells in 1% Triton X-100 containing
- 20 medium. An assay was not considered valid if the value for the 'spontaneous release' counts was in excess of 20% of the 'maximum release'.

Complement lysis of CD8+ T cells

- CD8+ T cells were removed from the splenocytes by a treatment with anti-CD8 monoclonal antibody (Pharmingen, San Diego, CA) followed by incubation with rabbit
- 25 complement (Sigma) for 45 min. at 37°C as described (Reference 33 below).

UPAP0020-001

PATENT

Murine T helper cell proliferation assay

A lymphocyte proliferation assay was used to assess the overall immunocompetence of lymphocytes and detect antigen specific dividing cells. Lymphocytes were harvested from spleens and prepared by removing the erythrocytes and washing several times with fresh media as described (Reference 34 below). The isolated cells were resuspended at a concentration of 5×10^6 cells/ml. A 100 μ l aliquot containing 5×10^5 cells was immediately added to each well of a 96 well microtiter flat bottom plate. Recombinant p24 protein was added to wells in triplicate resulting in the final concentration of 5 μ g/ml and 1 μ g/ml. The cells were incubated at 37°C in 5% CO₂ for three days. One μ Ci of tritiated thymidine was added to each well and the cells incubated for 12 to 18 hours at 37°C. Plates were harvested and the amount of incorporated tritiated thymidine was measured in a Beta Plate reader (Wallac, Turku, Finland). Stimulation Index was determined from the formula:

$$\text{Stimulation Index (SI)} = (\text{experimental count} / \text{spontaneous count})$$

Spontaneous count wells included 10% fetal calf serum, which will serve as irrelevant protein control. Similarly, spleenocytes from pCgag or control immunized mice routinely have an SI of 1 against their irrelevant protein target. To assure that cells are healthy, PHA or Con A (Sigma) was used as a polyclonal stimulator positive control.

Cytokine and Chemokine analysis of stimulated murine cells

Lymphocytes were harvested from spleens and the isolated cells were resuspended at a concentration of 5×10^6 cells/ml. A 100 μ l aliquot containing 5×10^5 cells was added to each well of a 96 well microtiter flat bottom plate. Recombinant p24 or envelope protein was added to wells in triplicate resulting in final concentrations of 5 μ g/ml and 1 μ g/ml. The cells were incubated at 37°C in 5% CO₂ for three days and the supernatants harvested. The cytokines and chemokines were measured with commercially available ELISA kits.

UPAP0020-001

PATENT

Intracellular staining for Interferon- γ of stimulated murine cells

Mice were given two injections with either pCgag DNA or pCgag DNA plasmid plus pIL- 15. One week later, splenocytes were harvested and cultured *in vitro* for five hours in media containing a p55 peptide cocktail (containing 122 15mers spanning HIV-1 p55 with 11aa overlaps) and BrefeldinA. After stimulation, cells were stained extracellularly with anti-mouse CD3 and anti-mouse CD8 antibodies and then intracellularly with anti-mouse IFN- γ . Dot plots display responses from CD3+/CD8+ lymphocytes.

Epitope Mapping

Splenocytes were resuspended in RPMI with 10% FCS (R10) at a concentration of 1×10^6 cells/ml. The series of 122 peptides obtained from the AIDS Reference and Reagent Repository were mixed as pools of 10 peptides per pool at a final concentration of 20 μ g/ml/peptide. Each peptide was included in two distinct pools for a total of 22 peptide pools. The pools were arranged in a matrix format and used for spleenocyte stimulation. IFN-gamma production was assessed by ELISPOT (R and D Systems). The plates were incubated at 37°C for approximately 24 hours. Each sample was assayed in triplicate.

RESULTS**Stimulation of Lymphocytes with CD3 and IL-15**

IL-15 was assessed for its ability to augment T cell effector activation, in a synergistic manner, with T cell receptor stimulation. PBMC's were isolated from HIV-1 infected individuals. PBMCs were stimulated with surface bound antibody to CD3 and then incubated overnight with IL-15. As expected, CD3 stimulation alone of PBMCs induced production of IFN- γ , while IL-15 supplement alone induced low to no response. However, a several fold increase in the number of cells secreting IFN- γ when lymphocytes were stimulated with CD3 and IL-15 together was observed (Figure 1). The stimulated populations were depleted of

UPAP0020-001

PATENT

CD4+ or CD8+ T cells and then supplemented with IL-15 and again tested for activity. Again, loss of CD8 cells depleted the activation signal. The data indicates that CD8+ effector T cells from chronically infected HIV-1 individuals can be expanded by IL-15/CD3 stimulation (Figure 2).

5 Antigen Specific IFN- γ Production of HIV-1 positive Samples Following IL-15 stimulation

The ability of IL-15 to enhance an HIV-1 antigen specific CD8+ response was assessed *in vitro*. Samples were collected from chronically infected HIV-1+ subjects who were being treated with combination anti-retroviral therapy (HAART). PBMCs were
 10 assessed for their ability to secrete IFN- γ following stimulation with HIV-1 specific peptides in the presence or absence of IL-15. PBMCs were stimulated with overlapping HIV-1 15 amino acid peptides that encompassed the entire open reading frame of HIV-1 gag protein. PBMCs from subjects stimulated with peptides exhibited expanded IFN- γ production when treated with IL-15 (Figures 3A and 3B) and there was a significant
 15 difference between the IFN- γ production with and without IL-15 ($p=.009$), (Figure 3C). Some subjects had high levels of IFN- γ secretion with IL-15 stimulation alone (Figure 3A), suggesting that they had partial T cell activation that was blocked and required cytokine supplement to be effective. This activity was clearly CD8 mediated as IFN- γ production was lost when the CD8 cell population was depleted (Figure 3D).

20 IL-15 enhances CD8+ CTL response in mice *in vivo*.

The above studies of HIV-1 responses and IL-15 established that IL-15 could enhance IFN- γ production in primed T cell populations. However, it was unclear what effect IL-15 would have on the functional induction of CD8+ T cells *in vivo*. To address this

UPAP0020-001

PATENT

question a mouse model system was used. Mice were vaccinated with HIV-1 plasmids as a means of delivering HIV-1 antigens and studying induction of CD8 immunity *in vivo*. The HIV-1 expressing plasmids were co-injected with either a plasmid that expressed IL-15, or a control plasmid and compared the resulting immune responses. In bulk CTL assays, co-injection with plasmids expressing HIV-1 envelope and LL-15 resulted in nearly 40% lysis of HIV-1 envelope-expressing targets at a 50:1 effector: target ratio compared to 11% lysis observed with envelope plasmid and control vector (Figure 4, panel A). These results were CD8 T cell dependent and indicate a significant effect of IL-15 on the effector T cell response.

10 **IL-15 induces MIP-1 β and IFN-g secretion following antigen stimulation in mice**

The vaccine-induced cellular immune responses were further extended by examining the expression profiles of the β -chemokine MIP-1 β as a marker of immune activation. Chemokines are important modulators of immune and inflammatory responses. They are especially important in the molecular regulation of trafficking of leukocytes from the vessels to the peripheral sites of host defense. Moreover, it has been previously reported that T cell-produced chemokines including MIP-1 β play a critical role in cellular immune expansion (Reference 24 below). Therefore, the level of chemokines produced by stimulated T cells may provide additional insight on the level and the quality of antigen-specific cellular immune response. Supernatant from the stimulated T cells (as described in Materials and Methods) was analyzed and tested for the release of MIP-1 β . Co-immunization with IL-15 resulted in high levels of secretion of MIP-1 β , (Figure 4, panel B).

Supernatants were assessed also for production of the Th1 cytokine, IFN- γ . Samples were obtained just prior to the cells being used in the CTL assay following a 3-day

UPAP0020-001

PATENT

lymphocyte stimulation with stimulator cells infected with recombinant vaccinia expressing HIV-1 envelope. Figure 4, panel C notes that splenocytes from mice co-injected with IL-15 induced higher levels of IFN- γ (120 pg/ml) compared to those injected with the plasmid vaccine alone or control. In contrast, no significant IL-4 production by any culture was
5 observed in these studies (data not shown).

Intracellular staining for IFN- γ and TNF- α .

To quantitate the T cell response to the HIV-1 vaccines, intracellular cytokine staining assays were performed. Immunized animals were sacrificed and spleenocytes were harvested and cultured *in vitro* for five hours in media containing the p55 cocktail mix and Brefeldin A.

10 The CD8⁺ CD3⁺ T cells were assayed by flow cytometry for production of IFN- γ or TNF- α (Figure 5, panel A and Figure 5, panel B). The IL-15 co-vaccinated animals exhibited high CD8 effector T cells responses with 2.6% of CD8⁺ T cells producing IFN- γ and 3.7% producing TNF- α . These data illustrate that IL-15 exhibited a profound effect on the functional CD8⁺ T cell response.

15 **Lymphocyte proliferation of murine splenocytes co-immunized with IL-15 and HIV-1 vaccines.**

The activation and proliferation of T helper lymphocytes is vital to humoral and cellular immune expansion. Spleenocytes from immunized mice were assessed in a basic lymphocyte proliferation assay for the ability to proliferate in response to stimulation with
20 recombinant HIV-1 antigen. IL-15 did not appear to have a dramatic impact on proliferative responses (Figure 6). However, IL-2 was used as a control and significant increases in splenocyte proliferation to gp120 env protein in the mice co-injected with IL-2 plasmids were clearly observed. The splenocytes of the mice co-injected with IL-2 resulted in stimulation

UPAP0020-001

PATENT

indexes that were at least 3-fold higher than those of mice immunized with control, pCgag alone, or pCEnv + IL-15 (Figure 6). This data further illustrates that IL-15 appears to enhance CD8 T cell function without dramatic expansion of T cell help. This also illustrates that this expansion by IL-15 is not dependent on IL-2. This suggests, in such a case, expansion of CD4 as well as CD8 effector function.

Epitope Mapping

To resolve the question of whether the enhancement of CD8+ T cell responses with IL-15 treatment was due to an increase in the number of epitopes responded to (i.e. epitope spreading) or due to an overall increase in the number of CD8+ T cells specific for the same epitope, the ELISPOT assay and the series of peptides obtained from the AIDS Reference and Reagent Repository (mixed as pools in a matrix format) was utilized. Two epitopes were identified. The dominant epitope was mapped to Gag amino acids 197 to 211 (AMQMLKETMEEAAE) (Figure 7). Paterson et al have previously defined AMQMLKETI (Reference 35 below) as the dominant CD8 epitope following immunization with a recombinant *L. monocytogenes* HIV-1 vaccine. A subdominant epitope, Gag amino acids 293-307 (FRDVDRFYKTRAE) (Figures 7) was further defined. There was no increase in the number of epitopes responded to as responses to both epitopes were observed in Gag only immunized groups. However, IL-15 dramatically expanded the magnitude of the responses to these epitopes. Only in the IL-15 co-vaccinated animals was the subdominant epitope clearly evident. IL-15 impacts the expansion of effector CD8 cells.

CD4 Knockout Mice

We observed that IL- 15 allowed antigen specific CD8 T cell expansion in PBMCs from HIV-1 infected individuals. We also observed significant CD8 effector cell induction

UPAP0020-001

PATENT

with out dependence on CD4 expansion in our vaccine model. Therefore, the contribution of CD4 helper T cells to the IL-15 immune expansion was brought into question. To address this issue, the ability of IL-15 to induce a CD8 effector population in the complete absence of CD4 cells was investigated. Mice homozygous for the $Cd4^{tm1Knn}$ targeted mutation
5 (Reference 36 below) were immunized. These mice have a block in CD4+ T-cell development and therefore most of the circulating lymphocytes are CD8 cells. Utilizing the plasmid co-immunization model where, on average, approximately 200 IFN-gamma producing cells per 1 million spleenocytes in normal mice are induced, in the absolute absence of CD4 cells IL-15 was not able to rescue an induced CD8 effector function (Figure
10 8 panel B). As the effect of IL-15 appeared not to be involved in CD4 expansion (Figure 6) the defect was reasoned to be due to lack of another function provided by T helper cells, CD4 T helper cells also provide help for CD8 expansion through activation of antigen presenting cells (APCs). In this model of APC activation, ligation of CD40, on the APC, to the T cell CD40 ligand upregulates B7 expression which allows for T cell activation. The B7
15 molecules provide costimulation. for CD8 T cell expansion in the context of MHC class I peptide presentation. Also, Bourgeois et al, (Reference 37 below) demonstrated that CD40L can directly impact CD8 memory cell development.

That the defect in CD4 help was manifesting itself at the level of a lack of costimulation was next considered and explored. To test this hypothesis mice were co-
20 immunized with plasmids containing both IL-15 and CD40L, along with pCgag. An anchored CD40L molecule was used. The anchored CD40L would be expressed locally and in trafficking immune cells but would not be secreted which would complicate the experiment (Reference 38 below). Such vaccination can provide costimulation *in trans* in a

UPAP0020-001

PATENT

plasmid model (Reference 38 below). Indeed, when pCgag was studied in combination with pCD40L, a Gag specific CD8 immune response was induced in the CD40 KO mice (Figure 8). This data further indicates that IL-15 impacts directly on memory CD8 lymphocytes. In the absence of CD4 cells IL-15 is not able to induce an antigen specific CD8 cellular response from naïve cells

DISCUSSION

The maintenance and enhancement an HIV-1 specific CD8 immune response has been the source of much investigation. Recent studies have reported that IL-15 may play an important role in supporting memory cell survival. It was observed in a mouse model that the presence of IL-15 can lead to memory cell division (Reference 39 below). *Ex vivo* functional analysis as well as studies using transgenic mice genetically lacking IL12, IL-15 or their specific receptors have been important in the characterization of the role played by IL-15. Indeed, Zhang and coworkers (Reference 39 below) demonstrated in an *in vivo* mouse model that IL-15 provides effective and discriminating stimulation of the memory phenotype, CD44^{hi} CD8⁺ T cells. And, Ku et al. (Reference 40 below) reported that the division of memory CD8⁺ T cells is stimulated by IL-15 but is inhibited by IL-2. It was also found that IL-2 inhibited proliferation of CD8⁺ memory T cells.

The work disclosed herein demonstrates that IL-15 is also particularly effective at inducing CD8⁺ effector T cells *in vitro* and *in vivo*. CD8⁺ T cells isolated from HIV-1 infected patients were able to secrete IFN-gamma in an antigen specific manner when incubated with peptide and IL-15. IL-15 works in concert with the TCR to stimulate lymphocytes to produce IFN- γ and assume an effector phenotype. In some subjects IL-15 led to production of IFN- γ in the absence of antigen. This suggests that in HIV infection some

UPAP0020-001

PATENT

cells are partially activated and this partial activation state can be rescued by IL-15. However, of importance is that a significant increase in effector function in all subjects when PBMCs were stimulated with both IL-15 and HIV-1 antigens.

Recently, von Adrian and colleagues (Reference 41 below) suggested that IL-15 stimulation of lymphocytes can result in CD8⁺ T cells proceeding to the memory cell phenotype directly from naïve cells. However, the data herein suggests that engagement of the TCR may lead to more complete activation of CD8⁺ T lymphocytes indicating that the impact of IL-15 alone on naïve cells would be minimal. In addition, it was suggested that IL-15 leads to memory cells that were non-functional (Reference 41 below). The data herein demonstrates that the IL-15 expansion resulted in fully functional CD8⁺ T cells as assessed in both the humans as well as the mouse studies. In the mouse, IL-15 dramatically increased CD8⁺ T cell responses as well as the enhancement of β -chemokine and IFN- γ responses, clearly indicating antigen specific expansion and building on prior work (References 33 and 42 below). This expansion of CD8⁺ T cell function was observed in the absence of CD4⁺ T cell expansion. Yet there is an important role for CD4 T cells in the development of the CD8 response. In studies in CD4 knock out mice the need for CD4 T cells could be circumvented by utilizing CD40L. This finding may be critically important for immunotherapy of viral infections.

Many immunotherapy strategies have focused on expanding CD8⁺ T cell responses. HIV-1 infection complicates immune therapy through viral induced immune suppression that contributes to a lack of effective CD4⁺ T cell help. In turn, this lack of help is thought to be responsible for an unproductive CD8⁺ T cell response. In general chronic infections require CD4⁺ help to maintain control of viral replication and this is likely the case for HIV-1

UPAP0020-001

PATENT

infection. Serbina et al (Reference 43 below) demonstrated that development of CD8+ cytotoxic T cells are dependent on CD4+ T cells. They further observed that in CD4 T cell knockout mice had decreased IL-15 production. Yet, IL-15 is not produced by CD4+ T cells. It is produced predominantly by stromal cells, monocytes, and macrophages. It is possible that there is some feed back mechanism where CD4+ T cells enhance the production of IL-15, and in the case of decreased CD4 help, ultimately CD8+ T cell functions are decreased. This feed back mechanism may explain why in three of six subjects' production of IFN- γ following the addition of IL-15 alone. In the absence of CD4, and thus at lower levels of IL-15, residual virus may only partially activate CD8+ T lymphocytes in subjects seropositive for HIV-1. Importantly, it appears here that IL-15 can be added in *trans* to replace defects caused by viral immunosuppression. Implications from this hypothesis should be considered in the area of immune therapy for HIV-1.

In summary IL-15 expanded CD8+ T cell effector function in mice and expanded functionality of CD8+ T cells isolated from subjects positive for HIV-1 infection. The use of IL-15 as a supplement to active immune therapy should be considered as an adjunct therapy to HAART.

REFERENCES (which are each incorporated herein by reference)

1. Ho, D., 1996, Therapy of HIV infections: problems and prospects. Bull. New York Acad. Med. 73, 37-45.
2. Finzi, D., Hermankova, M., Pierson, T., Carruth, LM., Buck C., 1997, Identification of a Reservoir for HIV-1 Patients on Highly Active Antiviral Therapy, Science, 278:1295-1300.

UPAP0020-001

PATENT

3. Wong, J., Hezareh, M., Günthard, H., Havlir, DV., 1997, Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia, *Science*, 278:1291-1294.
4. Rosenberg, ES., Altfield, M., Poon, SH., Phillips, MN., Wilkes, BM., Eldridge,
5 RL., Robbins, GK., D Aquilia R, T. Goulder, PJR, Walker, BD, 2000, Immune control of HIV-1 after early treatment of acute infection, *Nature*, 407:523.
5. Koup R, Safrit J, Cao Y, 1994, Temporal association of cellular immune responses with the initial control of viremia in primary Human immunodeficiency virus type 1 syndrome. *J of Virol*, 68:4650-4655.
- 10 6. Rinaldo C, Huang X, Fan Z, 1995, High Levels of Anti-Human Immunodeficiency Virus Type 1 (HIV-1) Memory Cytotoxic T-Lymphocyte Activity and Low Viral Load Are Associated with Lack of Disease in HIV-1 Infected Long-Term Nonprogressors, *J Virol.*, 69:5838-5842.
- 15 7. Cao, H., Kanki, P., Sankale, J., 1997, Cytotoxic T Lymphocyte Cross-Reactivity among Different HIV-1 Type 1 Clades: Implication for Vaccine Development, *J Virol*; 71:86158623.
8. Rowland-Jones S, Nixon D, Aldhous M.,1993, HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. *Lancet*, 341:860-86.
- 20 9. Rowland-Jones S, Sutton J, Ariyoshi K, 1995. HIV-specific T-cells in HIV-exposed but uninfected Gambian women. *Nature Medicine*, 1:59-64
10. Borrow, P, Lewicki, H, Wei, S, 1997, Antiviral pressure exerted by HIV-1 specific cytotoxic T lymphocytes during primary infection demonstrated by rapid selection of CTL escape virus *Nature Medicine*, 3:205-211.

UPAP0020-001

PATENT

11. Borrow, R. Shaw GM, 1998, Cytotoxic lymphocyte escape viral variant how important are they in viral evasions of immune clearance in vivo, *Immunology Rev*, 164:37-51.

12. Goulder PJ, Phillips RE, Colbert RA 1997, Late escape from an immunodominant cytotoxic T lymphocyte response associated with progression to AIDS, *Nature Medicine*, 3; 212-217.

13. Goulder PJ, Sewell AK, Lalloo DG, 1997, Pattern of immunodominance in HIV-1 specific cytotoxic T lymphocyte response in two human histocompatibility leukocyte antigens HLA identical siblings with HLA A0201 are influence by epitope mutations. *J Exp Med*, 185:1423-1433.

14. Phillips RE, Rowland-Jones, S Nixon, DF, 1991, Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition *Nature*, 354;453-459.

15. Koup, RA, 1994, Virus Escape from CTL recognition, *J Exp Med*, 180;779-782.

16. Ayyavoo, V., Mahboubi, A., Mahalingam, S., Ramalingam R., Kudchodkar, S., Williams, WV., Green, DR., Weiner, DB, 1997, HIV-1 vpr suppresses immune activation and apoptosis through regulation of nuclear factor KB, *Nature Medicine*, 3:1117-1122.

17. Kerkau, T., Bacik I., Bennink, JR., Yewdell, JW., Huning, T., Schimpl, A., Schubert, U, 1997, The human immunodeficiency virus type I (HIV-1) vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules, *J Exp Med.*, 185:1295-1305.

UPAP0020-001

PATENT

18. Lenburg, M.E., and Landau N.R., 1993, VP1 induced degradation of CD4: Requirement for specific amino acid residues in the cytoplasmic domain of CD4, *J Virol*, 67:6542-6550.

19. Anderson, S., Shugar, D.C., Swanstrom, R., Garcia, J.V., 1993, Nef from primary isolates of human immunodeficiency virus type I suppressed surface CD4 expression in human and mouse T cells *J Virol* 67:4923-4931.

20. Rosenberg, ES, Billings, JM, Caliendo, AM, et al., Vigorous HIV-1 Specific CD4 T cell Responses Associated with Control of Viremia, *Science*, 278:1447-1450, (1997).

21. Kalam, SA, Walker BD., 2000, The critical need for CD4 help in maintaining effective cytotoxic T Shankar P. Russo M. Harnisch B. Patterson M. Skolnik P. Lieberman J. Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection. *Blood*. 96(9):3094-101

22. Murali-Krishna, K., Lau, LL., Sambliara, S., Lemonnier, F., Altman, J., Ahmed, R., 1999, Persistence of Memory CD8 T Cells in MHC Class I-Deficient Mice, *Science*, 286:1377-1383.

23. Tagaya, Y., Bamford, RN., Defilippis, AP, Waldmann, TA., 1996, IL-15: A Pleiotropic Cytokine with Diverse Receptor/Signaling Pathways Whose Expression is Controlled at Multiple Pathways. *Immunity* 4:329-336.

24. Chang, KH, Kim, JM, Kim HY, Sorig, YG, Choi, YH, Park, YS, Cho, JH, Hong, SK., 2000, Spontaneous Programmed Cell Death of Peripheral Blood Mononuclear Cells from HIV-Infected Persons is Decreased with IL-15. *Yonsei Medical Journal*, 41:112-118.

UPAP0020-001

PATENT

25. Naora H., Gougeon, ML., 1999, Enhanced Survival and Potent Expansion of the Natural Killer Population of HIV Infected Individuals by Exogenous IL-15. *Immunology Letters*, 68:359-367.
26. Lin, SJ, Roberts, RL, Ark, BJ, Nguyen, OH, Thomas, EH, Stichn, ER., 1997,
5 Human Immunodeficiency Virus (HIV) Type-1 GP120-Specific Cell Mediated Cytotoxicity Interleukin-2 (IL-2), IL-12, and IL-15. *Clin. Imm. Immpath*, 82:163-173.
27. Loubeau, M., Ahmad A., Toma E., Menezes, J., 1997, Jo. Enhancement of Natural Killer and Antibody Dependent Cytotoxic Activities of the Peripheral Mononuclear Cells of HIV-Infected Patients by Recombinant IL-15. *AIDS* 16:137-145.,
- 10 28. Kacani, L., Sprizl GM., Erdei, A., Dierich, MP, 1999, Interleukin-15 Enhances HIV-1 Driven Polyclonal B-Cell Response in Vitro. *Exp and Clin Immun*, 16:167-179.
29. Kacani, L., Stoiber H., Dierich, MP, 1997, Role of IL-15 in HIV-1 Associated Hypergammaglobulinanemia. *Clin Exp Imm* 108:14-18.
30. Agostini, C., Zambello, R., Perrin A., Piazzo, F., Siviero, M., Basso, U.,
15 Borfolin, M., Trentin L., Semenatao, G., 1999, CD8 T-Cell Infiltration in Extravascular Tissues of Patients with Human Immunodeficiency Virus Infection. Interleukin 15 Upmodulates Co-Stimulatory Pathways Involved in the Antigen Presenting Cells of T-cell Interaction. *Blood*, 93:1277-1286.
31. Patki, AH., Quinone S., Mateo, ME., Dorazio, D., Yen-Lieberman B., Boom
20 WH, Thomas, EK., Ledermann MM, 1996, Activation of antigen Induced Lymphocyte Proliferation by Interleukin-15 Without the Mitogenic Effect of Interleukin-2 That May Induce Human Immunodeficiency Virus-1 Expression. *JCI*, 98:616-621.

UPAP0020-001

PATENT

32. Lucey DR., Pinto LA, Bethke, FR., Rusnak J., Mekher GP, Hashemi, FN, Landay, AI., Kessler, HA, Paxton, RJ., Grabstein, K., Shearer GM., In Vitro Immunologic and Virologic Effects of Interleukin-15 on Peripheral Blood Mononuclear Cells from Normal Donors and Human Immunodeficiency Virus Type-1 Infected Patients. *Clin Diagn Lab Imm*,
 5 4:43-48.

33. Kim, JJ. Trivedi, NN., Nottingham, LK., Morrison, L., Tsai, A., Hu, Y., Mahalingam, S., Dang, K., Alm, L., Doyle, NK., Wilson, D., Chattergoon, MA., Chalian, AA., Boyer, JD., Agadjanyan, M., Weiner, DB., 1998, Modulation of amplitude and direction of in vivo immune responses by co-administration of cassettes with DNA
 10 immunogens, *Eur. J Immunol.* 28:1089-1103.

34. Kim JJ. Tsai A. Nottingham LK. Morrison L. Cuning DM. Oh J. Lee DJ. Dang K. Dentchev T. Chalian AA. Agadjanyan MG. Weiner DB, 1999, Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo, *Journal of Clinical Investigation.* 103:869-77.

15 35. Mata, M., Travers, PJ. Liu, Q., Frankel, FR., Paterson, Y., 1998, The MHC Class I Restricted Immune Response to HIV-1 gag in Balb/c Mice Selects a Single Epitope That Does not Have a Predictable MHC Binding- Motif and Binds to Kd Through Interactions Between a Glutamine at PS and Pocket D, *Jo of Immun.*, 161:2985-2993.

36. McCarrick III JW, Partics JR, Seong RH, Solter D, Knowles BB. 1993.
 20 Positive-negative selection gene targeting with the diphtheria toxin A-chain gene in mouse embryonic stem cells. *Transgenic Res* 2:183-190.

37. Bourgeois, C., Rocha, B., Tanchot, C., A Role for CD40 Expression on CD8+ T Cells in the Generation of CD8+ T Cell Memory, 2002, *Science* 297:2060-2063.

UPAP0020-001

PATENT

38. Sin JI. Kim JJ. Zhang D. Weiner DB. Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo. *Human Gene Therapy*. 12:1091-102, 2001.

5 39. Zhang, X., Sun, S., Hwang, I., Tough, DF. Sprent, 1998, J., *Immunity*, 8:591-599.

40. Ku, CC., Murakami, M., Sakamoto, A., Kappler, J., Marrack. P., 2000, Control of Homeostasis of CD8 Memory T Cells by Opposing Cytokines, *Science*, 288:675-678.

10 41. Manjunath, N., Shankar, P., Wan, J., Weninger, W., Crowley, MA. Hieshmina, K., Springer, TA., Fan, X., Shen, H., Lieberman, J., von Andrian, UH., 2001, Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes, *Journal of Clinical Investigation*, 108:871-878.

42. Moore AC. Kong WP. Chakrabarti BK. Nabel GJ. Effects of antigen and
15 genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. *Journal of Virology*. 76(1):243-50, 2002 Jan

43. Serbina NV. Lazarevic V. Flynn JL 2001, CD4(+) T cells are required for the development of cytotoxic CD8(+) T cells during *Mycobacterium tuberculosis* infection. *Journal of Immunology*. 167:6991-7000.

20 Example 2

There is a requirement for CD4(+) Th cells and the production of IFN-gamma to control viral replication in immune compromised individuals as well as in antitumor immunology. Data from experiments performed demonstrate that the requirement for T cell

UPAP0020-001

PATENT

help for expansion of CD8 effect or T cells can be replaced by local production of IL-15 and CD40L at the vaccine site. Experiments using mice in which CD4(+) T cells were eliminated by gene knockout of the MHC class II beta-chain (MHC II KO), reveal that priming of the animals with antigen gag + IL-15 + CD40L leads to activation of CD8 T cells. Activation is measured by IFN-gamma production as spots. Greater than 50 spots in this assay are positive. These data, shown in Figure 9, illustrate a simple method for the activation of effect or CD8 T cells independently of CD4(+) T cell help. These studies have importance for the treatment of immunocompromised individuals.

Example 3

Human, mouse, and simian IL-15 cDNA encodes a 162 amino acid (aa) residue precursor protein containing a 48 aa residue leader that is cleaved to generate the 114 aa residue mature IL-15. Human IL-15 shares approximately 97% and 73% sequence identity with simian and mouse IL-15, respectively. Both human and simian IL-15 are active on mouse cells. Although the structure of IL-15 has not been determined, it is predicted to be similar to IL-2 and other members of the four-helix bundle cytokine family. (Grabstein, K. et al. (1994) Science 264:965, Anderson, D.M. et al. (1995) Genomics 25:701; and Bamford, R.N. et al. (1995) Cytokine 7:595, Brandhuber, B.J. et al. (1987) Science 238:1707, both of which are incorporated herein by reference.)

IL-15 mRNAs have been detected in heart, lung, liver, placenta, skeletal muscle, adherent peripheral blood mononuclear cells, APCs (Dendritic cells), and epithelial and fibroblast cell lines. However, IL-15 mRNA is not detectable in activated peripheral blood T cells that contain high levels of IL-2 mRNA. IL-15 has been shown to stimulate the growth of natural killer cells, activated peripheral blood T lymphocytes, tumor infiltrating

UPAP0020-001

PATENT

lymphocytes (TILs), and B cells. In addition, IL-15 has also been shown to be a chemoattractant for human blood T lymphocytes, to induce lymphokine-activated killer (LAK) activity in NK cells, and to induce the generation of cytolytic effector cells. (Armitage, R.J. et al. (1995) J. Immunol. 154:483; P. Wilkinson and F. Liew (1995) J. Exp. Med. 181:1255; Grabstein, K. et al. (1994) Science 264:965; Giri, J.G. et al. (1994) EMBO J. 13:2822; and Giri, J.G. et al. (1995) EMBO J. 15:3654, each of which is incorporated herein by reference.)

Because IL-15 is a prototypic Th1 cytokine, and by virtue of its activity as a stimulator of T cells, NK cells, LAK cells, and TILs, IL-15 is an exciting candidate for use as a molecular adjuvant along with DNA vaccines such as HIV vaccines to enhance cellular immune responses. IL-15 expands HIV specific CTLs, and overproduction of IL-15 is associated with inflammatory diseases such as Crohn's disease.

Northern Blot analysis indicates widespread constitutive expression of IL-15. Control of expression occurs post-transcriptionally at the level of translation and translocation (intracellular trafficking). IL-15 mRNA includes a number of elements that impede its translation into protein including: 1) the 5' AUGs are burdened with upstream AUGs that interfere effective IL-15 translation (5 in mice, 12 in humans); 2) the start codon for the IL-15 coding sequence has a weak KOZAK context (GTAATGA); and 3) presence of a negative element in the C-terminus of the IL-15 mature protein coding sequence. (Grabstein et al., (1994) Science 264:965-968, Bamford et al., (1996) PNAS 93:2897-2902; Bamford et al., (1998) J. Immunol 160:4418-4426; and Kozak et al., (1991) J. Cell Biol. 115:887-903, which are each incorporated herein by reference. Each of these three controls may be eliminated to improve expression.

UPAP0020-001

PATENT

Native IL-15 isoforms contain two leader peptides: a 21 aa signal peptide (SSP) or a 48 aa signal peptide (LSP) (Waldmann et al. Ann. Rev> Immunol. (1999) 17:19-49, which is incorporated herein by reference.

The following strategy for increasing expression of IL-15 through optimization of IL-
5 15 DNA constructs for immunization was followed. Primers were designed to amplify IL-15 from start of signal peptide, thus upstream inhibitory AUGs are not present in the final IL-15 message. Primers were designed to include a strong KOZAK context (GCCGCCACC). The C-terminus negative regulatory element was removed using PCR antisense primer design. The primers are set forth in Figure 10.

10 The following strategy for increasing expression of IL-15 through replacement of the 48 amino acid IL-15 signal peptide (LSP) with IgE leader was performed. Sense primers were designed to start after 48 aa LSP while antisense primer amplified from stop site. Primers were designed to include a strong KOZAK context (GCCGCCACC). Sense primer was designed to contain the sequence for IgE leader sequence plus a ATG start site. The
15 primers are set forth in Figure 11.

Various constructs were prepared and used to transfect RD cells. IL-15 protein production was measured for the various constructs. The data is shown in Figures 12, panels A-C. Figure 13A shows a comparison of expression by human constructs that include coding sequences for the 21 amino acid signal peptide linked to IL-15 (IL-15 SSP – left) and coding
20 sequences for the human 48 amino acid signal peptide (IL-15 LSP – right). Figure 12, panel B shows a comparison of expression by human constructs that include coding sequences for the 48 amino acid signal peptide (human IL-15 LSP – left) and coding sequences for the IgE signal peptide (human IL-15-IgE – right). Figure 12, panel C shows a comparison of

UPAP0020-001

PATENT

expression by Macaque constructs that include coding sequences for the 48 amino acid signal peptide (Mac IL-15 LSP – left) and coding sequences for the IgE signal peptide (Mac IL-15-IgE – right).

IL-15 bioactivity was measured of IL-15 protein produced from the various
5 constructs. The data is shown in Figures 13 panels A and B. Figure 13, panel A shows a comparison of IL-15 bioactivity between human constructs that include the 48 amino acid signal peptide (human IL-15 LSP – left) and coding sequences for the IgE signal peptide (human IL-15-IgE – right). Figure 13, panel B shows a comparison of IL-15 bioactivity between Macaque constructs that include coding sequences for the 48 amino acid signal
10 peptide (Mac IL-15 LSP – left) and coding sequences for the IgE signal peptide (Mac IL-15-IgE – right).

A construct was made using the expression vector pVAX with an insertion of an IL-15 coding sequence linked to coding sequence for an IgE signal peptide. Construct encoding HIV-1 Gag were also generated. Immunological experiments were performed comparing the
15 effects on immune responses using IL-15 engineered plasmids in combination with HIV-1 Gag. Balb/c Mice were vaccinated according to the immunization schedule shown in Figure 14.

Immune responses were studied by comparing restimulation of antigen-specific IFN- γ production 5 weeks following the third immunization. The data is shown in Figure 15.
20 Vaccine groups included naïve mice, mice vaccinated with the vector pCDN3, mice vaccinated with constructs that encoded HIV-1 Gag, mice vaccinated with constructs that encoded HIV-1 Gag and IL-15 linked to the 48 amino acid signal peptide and mice vaccinated with constructs that encoded HIV-1 Gag o linked to the IgE signal peptide.

UPAP0020-001

PATENT

Example 4

An engineered IL-15 plasmid vaccine was constructed by removing the native IL-15 Kozak region, AUG's and UTRs. The engineered IL-15 plasmid was provided with the coding sequence for IgE signal peptide. The engineered IL-15 was expressed at a level 30 to 50 times greater than that observed with a comparable wild type plasmid. The immune response observed in mice co-immunized with engineered IgE signal-IL-15 and HIV-1 gag constructs were significantly times greater than mice immunized with the HIV-1 gag construct alone. Data is shown in Figure 16.

Example 5

Isolated cDNA that encodes the immunomodulating proteins are useful as a starting material in the construction of constructs that can produce that immunomodulating protein. In some embodiments, constructs are provided in which coding sequences for one of the following immunomodulatory proteins are linked to the IgE signal peptide. In some embodiments, such constructs are provided as part of vaccines and immunomodulating compositions such as those described herein.

Using standard techniques and readily available starting materials, a nucleic acid molecule that encodes an immunomodulating protein may be prepared and incorporated into constructs, vectors, vaccines etc as described herein.

Genbank Accession number AF031167 refers to the complete coding sequence of human IL-15 mRNA. Genbank Accession numbers Y09908, X91233, X94223 and X94222 also refer to human IL-15 sequences. Each sequence is incorporated herein by reference.

Genbank Accession number L07414 refers to the complete coding sequence of human CD40-ligand mRNA. The sequence is incorporated herein by reference.

UPAP0020-001

PATENT

The GENBANK Accession number for the nucleotide and amino acid sequences for Bax is L22473, which is incorporated herein by reference.

The GENBANK Accession number for the nucleotide and amino acid sequences for TRAIL is U37518 or AF023849, which are incorporated herein by reference.

5 The GENBANK Accession number for the nucleotide and amino acid sequences for TRAILrecDRC5 is U90875 or AF016266, which are incorporated herein by reference. Also incorporated by reference are TRAIL-R2 AF016849; TRAIL-R3 AF014794; and TRAIL-R4 AF021232.

10 The GENBANK Accession number for the nucleotide and amino acid sequences for RANK is AF018253 which is incorporated herein by reference.

The GENBANK Accession number for the nucleotide and amino acid sequences for RANK LIGAND is AF019047 or AF333234, which are incorporated herein by reference.

The GENBANK Accession number for the nucleotide and amino acid sequences for Ox40 is X75962, which is incorporated herein by reference.

15 The GENBANK Accession number for the nucleotide and amino acid sequences for Ox40 LIGAND is X79929 or AB007839, which are incorporated herein by reference.

The GENBANK Accession number for the nucleotide and amino acid sequences for NKG2D is AF461811 or X54870, which are incorporated herein by reference.

20 The GENBANK Accession number for the nucleotide and amino acid sequences for MICA is X92841, which is incorporated herein by reference.

The GENBANK Accession number for the nucleotide and amino acid sequences for MICB is U65416, which is incorporated herein by reference.

UPAP0020-001

PATENT

The GENBANK Accession number for the nucleotide and amino acid sequences for NKG2A is X54867, which is incorporated herein by reference.

The GENBANK Accession number for the nucleotide and amino acid sequences for NKG2B is X54868, which is incorporated herein by reference.

5 The GENBANK Accession number for the nucleotide and amino acid sequences for NKG2C is X54869 or Aj0016984, which are incorporated herein by reference.

The GENBANK Accession number for the nucleotide and amino acid sequences for NKG2E is L14542, which is incorporated herein by reference.

10 The GENBANK Accession number for the nucleotide and amino acid sequences for NKG2F is AH006173, U96845 or U96846, which are incorporated herein by reference.

The GENBANK Accession number for the nucleotide and amino acid sequences for CD30 is M83554, (Durkop, H et al. Cell 68 (3), 421-427 (1992)) which is incorporated herein by reference.

15 The GENBANK Accession number for the nucleotide and amino acid sequences for CD153 (CD30L) is L09753, (Smith, C.A., et al. Cell 73 (7), 1349-1360 (1993)) which are incorporated herein by reference

The GENBANK Accession number for the nucleotide sequence for Fos is K00650 or V01512, which are each incorporated herein by reference.

20 The GENBANK Accession number for the nucleotide sequence for c-jun J04111 or M29039, which are each incorporated herein by reference.

The GENBANK Accession number for the nucleotide sequence for Sp-1 is BC021101, BC005250, BC002878, M31126, J02893 or X15102, which are each incorporated herein by reference.

UPAP0020-001

PATENT

The nucleotide sequence for Ap1 can be identified as described in Lee et al, 1987 Cell 49:741-752, Rauscher et al. 1988 Science 240:1010-1016, and Chiu et al, 1988 Cell 54:541-552, which are each incorporated herein by reference.

The GENBANK Accession number for the nucleotide sequence for Ap-2 is M36711,
5 which is incorporated herein by reference.

The GENBANK Accession number for the nucleotide sequence for p38 is U66243,
which is incorporated herein by reference.

The GENBANK Accession number for the nucleotide sequence for p65Rel is
L19067, which is incorporated herein by reference.

10 The GENBANK Accession number for the nucleotide sequence for MyD88 is
U70451, which is incorporated herein by reference.

The GENBANK Accession number for the nucleotide sequence for IRAK is
NM001569, which is incorporated herein by reference.

The GENBANK Accession number for the nucleotide sequence for TRAF6 is
15 U78798, which is incorporated herein by reference.

The nucleotide sequence for Ikb can be found as described in Gilmore et al. Trends
Genet 1993 Dec;9(12):427-33, which is incorporated herein by reference.

The GENBANK Accession number for the nucleotide sequence for NIK is Y10256,
which is incorporated herein by reference.

20 The nucleotide sequence for SAP K can be found as described in Franklin et al.
Oncogene. 1995 Dec 7;11(11):2365-74. which is incorporated herein by reference.

The GENBANK Accession number for the nucleotide sequence for SAP1 is M85164
or M85165, which are each incorporated herein by reference.

UPAP0020-001

PATENT

The GENBANK Accession number for the nucleotide sequence for JNK2 is L31951, which is incorporated herein by reference.

The GENBANK Accession number for the nucleotide sequence for JNK1B2 is U35005; which is incorporated herein by reference.

5 The GENBANK Accession number for the nucleotide sequence for JNK1B1 is U35004; which is incorporated herein by reference.

The GENBANK Accession number for the nucleotide sequence for JNK2B2 is U35003; which is incorporated herein by reference.

10 The GENBANK Accession number for the nucleotide sequence for JNK2B1 is U35002; which is incorporated herein by reference.

The GENBANK Accession number for the nucleotide sequence for JNK1A2 is U34822; which is incorporated herein by reference.

The GENBANK Accession number for the nucleotide sequence for JNK2A1 is U34821; which is incorporated herein by reference.

15 The GENBANK Accession number for the nucleotide sequence for JNK3A1 is U34820; which is incorporated herein by reference.

The GENBANK Accession number for the nucleotide sequence for JNK3A2 is U34819, which is incorporated herein by reference.

20 The GENBANK Accession number for the nucleotide sequence for NF-kappa-B2, p49 splice form is A57034, which is incorporated herein by reference.

The GENBANK Accession number for the nucleotide sequence for NF-kappa-B2, p100 splice form is A42024, which is incorporated herein by reference.

UPAP0020-001

PATENT

The GENBANK Accession number for the nucleotide sequence for NF-kappa-B2, p105 splice form is S17233, which is incorporated herein by reference.

The GENBANK Accession number for the nucleotide sequence for NF-kappa-B 50K chain precursor is A37867, which is incorporated herein by reference.

5 The nucleotide sequence for NFkB p50 is described in Meyer R., et al. (1991) Proc. Natl. Acad. Sci. USA 88(3), 966 970, which is incorporated herein by reference.

The nucleotide and amino acid sequences of human IL-1 α are well known and set forth in Telford, et al. (1986) Nucl. Acids Res. 14:9955-9963, Furutani, et al. (1985) Nucl. Acids Res. 14:3167-3179, March, et al. (1985) Nature 315:641-647, and accession code
10 Swissprot PO1583, which are each incorporated herein by reference.

The nucleotide and amino acid sequences of human IL-2 are well know and set forth in Holbrook, et al. (1984) Proc. Natl. Acad. Sci. USA 81:1634-1638, Fujita, et al. (1983) Proc. Natl. Acad. Sci. USA 80:7437-7441, Fuse, et al. (1984) Nucl. Acids Res. 12:9323-9331, Taniguchi, et al. (1983) nature 302:305-310, Meada, et al. (1983) Biochem. Biophys.
15 Res. Comm. 115:1040-1047, Devos, et al. (1983) Nucl. Acids Res. 11:4307-4323, and accession code Swissprot PO1585, which are each incorporated herein by reference.

The nucleotide and amino acid sequences of human IL-4 are well know and set forth in Arai, et al. (1989) J. Immunol. 142:274-282 Otsuka, et al. (1987) Nucl. Acids Res. 15:333-344, Yokota, et al. (1986) Proc. Natl. Acad. Sci USA 83:5894-5898, Noma, et al. (1984)
20 Nature 319:640-646, Lee, et al. (1986) Proc. Natl. Acad. Sci. USA 83:2061-2063, and accession code Swissprot 05112 (the accession code for murine IL-4 is Swissprot 07750), Which are each incorporated herein by reference.

UPAP0020-001

PATENT

The nucleotide and amino acid sequences of human IL-5 are well known and set forth in Campbell, et al. (1987) Proc. Natl. Acad. Sci. USA 84:6629-6633, Tanabe, et al. (1987) J.Biol. Chem. 262:16580-16584, Campbell, et al. (1988) Eur. J. Biochem. 174:345-352, Azuma, et al. (1986) Nucl. Acids Res. 14:9149-9158, Yokota, et al. (1986) Proc. Natl. Acad. Sci. USA 84:7388-7392, and accession code Swissprot PO5113, which are each incorporated herein by reference.

The nucleotide and amino acid sequences of human IL-10 are well know and set forth in Viera, et al. (1991) Proc. Natl. Acad. Sci. USA 88:1172-1176, and accession code Swissprot P22301.

The nucleotide and amino acid sequences of human IL-15 are well known and set forth in Grabstein, et. al. (1994) Science 264:965-968, and accession code Swissprot UO3099, which are each incorporated herein by reference.

The nucleotide and amino acid sequences of human IL-18 are well known and set forth in Ushio, et al. (1996) J. Immunol. 156:4274-4279, and accession code D49950, which are each incorporated herein by reference.

The nucleotide and amino acid sequences of human TNF- α are well known and set forth in Pennica, (1984) Nature 312:724-729, and accession code Swissprot PO1375, which are each incorporated herein by reference.

The nucleotide and amino acid sequences of human TNF- β are well known and set forth in Gray, (1984) Nature 312:721-724, and accession code Swessprot PO1374, which are each incorporated herein by reference. ino acid sequences of human IL-10 are well know and set forth in Viera, et al. (1991) Proc. Natl. Acad. Sci. USA 88:1172-1176, and accession code Swissprot P22301, which are each incorporated herein by reference.

UPAP0020-001

PATENT

The complete coding sequence for human interleukin 12 mRNA, is set forth in Genbank Accession Number AF180563 (P40 mRNA) and AF180562 (P35 mRNA) and U.S. Patent Number 5,840,530, which are each incorporated herein by reference.

Sequence information for MadCAM-1 is found at Genbank Accession Number
5 U80016 (Leung, E., et al, Immunogenetics 46 (2), 111-119 (1997)) , which are each incorporated herein by reference.

Sequence information for MadCAM-1 is found at Genbank Accession Number U43628 (Shyjan, A.M., et al, J. Immunol. 156 (8), 2851-2857 (1996)) , which are each incorporated herein by reference.

10 Sequence information for NGF is found at Genbank Accession Number M57399 (Kretschmer, P.J., et al., Growth Factors 5, 99-114 (1991)) , which are each incorporated herein by reference.

Sequence information for IL-7 is found at Genbank Accession Number J04156 (Goodwin, R.G., et al., Proc. Natl. Acad. Sci. U.S.A. 86 (1), 302-306 (1989)) , which are each
15 incorporated herein by reference.

Sequence information for VEGF is found at Genbank Accession Number M32977 (Leung, D.W., et al., Science 246, 1306-1309 (1989)) , which are each incorporated herein by reference.

Sequence information for TNF-R is found at Genbank Accession Number M60275
20 (Gray, P.W., et al. Proc. Natl. Acad. Sci. U.S.A. 87, 7380-7384 (1990)) , which are each incorporated herein by reference.

UPAP0020-001

PATENT

Sequence information for TNF-R is found at Genbank Accession Number M63121 (Himmler, A., et al. DNA Cell Biol. 9, 705-715 (1990)), which are each incorporated herein by reference.

Sequence information for Fas is found at Genbank Accession Number M67454 (Itoh, N., et al., Cell 66 (2), 233-243 (1991)), which are each incorporated herein by reference.

Sequence information for CD40L is found at Genbank Accession Number L07414 (Gauchat, J.F.M., et al. FEBS Lett, 315, 259-266 (1992), which are each incorporated herein by reference.

Sequence information for IL-4 is found at Genbank Accession Number M23442 (Arai, N., et al., J. Immunol. 142 (1), 274-282 (1989)), which are each incorporated herein by reference.

Sequence information for IL-4 is found at Genbank Accession Number M13982 (Yokota, T., et al. Proc. Natl. Acad. Sci. U.S.A. 83 (16), 5894-5898 (1986)), which are each incorporated herein by reference.

Sequence information for CSF is found at Genbank Accession Number M37435 (Wong, G.G., et al. Science 235 (4795), 1504-1508 (1987)), which are each incorporated herein by reference.

Sequence information for G-CSF is found at Genbank Accession Number X03656 (Nagata, S., et al, EMBO J. 5 (3), 575-581 (1986)), which are each incorporated herein by reference.

Sequence information for G-CSF is found at Genbank Accession Number X03655 (Nagata, S., et al., EMBO J. 5 (3), 575-581 (1986)), which are incorporated herein by reference.

UPAP0020-001

PATENT

Sequence information for GM-CSF is found at Genbank Accession Number M11220 (Lee, F., et al., Proc. Ntl. Acad. Sci. U.S.A. (13), 4360-4364 (1985)) which are incorporated herein by reference.

Sequence information for GM-CSF is found at Genbank Accession Number M10663
5 (Wong, G.G., et al., Science 228 (4701), 810-815 (1985)) which are incorporated herein by reference.

Sequence information for M-CSF is found at Genbank Accession Number M27087 (Takahashi, M., et al., Biochem. Biophys. Res. Commun. 161 (2), 892-901 (1989)) which are incorporated herein by reference.

10 Sequence information for M-CSF is found at Genbank Accession Number M37435 (Wong G.G., et al., Science 235 (4795), 1504-1508 (1987)) which are incorporated herein by reference.

Sequence information for LFA-3 is found at Genbank Accession Number Y00636 (Wallner, B.P., et al., J. Exp. Med. 166 (4), 923-932 (1987)) which are incorporated herein by
15 reference.

Sequence information for ICAM-3 is found at Genbank Accession Number X69819 which are incorporated herein by reference.

Sequence information for ICAM-2 is found at Genbank Accession Number X15606 (Staunton, D.E., et al., Nature 339 (6219), 61-64 (1989)) which are incorporated herein by
20 reference.

Sequence information for ICAM-1 is found at Genbank Accession Number J03132 (Staunton, D.E., et al., Cell 52 (6), 925-933 (1988)) which are incorporated herein by reference.

UPAP0020-001

PATENT

Sequence information for PECAM is found at Genbank Accession Number M28526 (Newman, P.J., et al., Science 247, 1219-1222 (1990) which are incorporated herein by reference.

5 Sequence information for P150.95 is found at Genbank Accession Number Y00093 (Corbi, A.L., et al., EMBO J. 6 (13), 4023-4028 (1987)) which are incorporated herein by reference.

Sequence information for Mac-1 is found at Genbank Accession Number J03925 (Corbi, A.L., et al., J. Biol. Chem. 263 (25), 12403-12411 (1988)) which are incorporated herein by reference.

10 Sequence information for LFA-1 is found at Genbank Accession Number Y00796 (Larson, R., et al., J. Cell Biol. 108 (2), 703-712 (1989)) which are incorporated herein by reference.

Sequence information for CD34 is found at Genbank Accession Number M81104 (Simmons, D.L. et al., J. Immunol. 148, 267-271 (1992)) which are incorporated herein by
15 reference.

Sequence information for RANTES is found at Genbank Accession Number M21121 (Schall, T.J., et al., J. Immunol. 141, 1018-1025 (1988)) which are incorporated herein by reference.

Sequence information for IL-8 is found at Genbank Accession Number M28130
20 (Mukaida, N., et al., J. Immunol. 143 (4), 1366-1371 (1989)) which are incorporated herein by reference.

UPAP0020-001

PATENT

Sequence information for MIP-1 α is found at Genbank Accession Number U72395 (Fridell, R.A., et al., J. Cell. Sci 110 (pt 11), 1325-1331 (1997)) which are incorporated herein by reference.

5 Sequence information for E-selecton is found at Genbank Accession Number M24736 (Bevilacqua, M.P., et al., Science 243 (4895), 1160-1165 (1989)) which are incorporated herein by reference.

Sequence information for CD2 is found at Genbank Accession Number M14362 (Sewell, W.A., et al. Proc. Natl. Acad. Sci. U.S.A. 83, 8718-8722 (1986); Proc. Natl. Acad. Sci. U.S.A. 84, 7256-7256 (1987)) which are incorporated herein by reference.

10 Sequence information for MCP-1 is found at Genbank Accession Number S69738 (Li, Y.S., et al., Mol. Cell. Biochem. 126 (1), 61-68 (1993)) which are incorporated herein by reference.

Sequence information for L-selection is found at Genbank Accession Number X16150 (Tedder, T.F., et al., J. Exp. Med. 170 (1), 123-133 (1989)) which are incorporated
15 herein by reference.

Sequence information for P-selection is found at Genbank Accession Number M25322 (Johnston, G.I., et al., Cell 56, 1033-1044 (1989)) which are incorporated herein by reference.

Sequence information for FLT is found at Genbank Accession Number X94263
20 (Mandriota, S.J., et al., J. Biol. Chem. 271 (19), 11500-11505 (1996)) which are incorporated herein by reference.

UPAP0020-001

PATENT

Sequence information for FLT is found at Genbank Accession Number X51602 (Shibuya, M. et al. Oncogene 5 (4), 519-524 (1990) Han, H.J., et al. Hum. Mol. Genet. 2 (12), 2204 (1993)) which are incorporated herein by reference.

Sequence information for Apo-1 is found at Genbank Accession Number X63717
5 (Oehm, et al, J. Biol.Chem., (1992), 267 (15), 10709-15) which are incorporated herein by reference.

Sequence information for Fas is found at Genbank Accession Number M67454 (Itoh, et al., Cell, (1991), 66 (2), 233-43) which are incorporated herein by reference.

Sequence information for TNFR-1 is found at Genbank Accession Number M67454
10 (Nophar, et al., EMBO J., 1990, 9(10), 3269-78) which are incorporated herein by reference.

Sequence information for p55 is found at Genbank Accession Number M58286 (Loetscher, et al., Cell, 1990, 61, 351-359) which are incorporated herein by reference.

Sequence information for WSL-1 is found at Genbank Accession Number Y09392 (Kitson, et al., Nature, 1996, 384 (6607), 372-5) which are incorporated herein by reference.

15 Sequence information for DR3 is found at Genbank Accession Number U72763 (Chinnaiyan, et al., Science, 1996, 274 (5829), 990-2) which are incorporated herein by reference.

Sequence information for TRAMP is found at Genbank Accession Number U75381 (Bodmer, et al., Immunity, 1997, 6 (1), 79-88) which are incorporated herein by reference.

20 Sequence information for Apo-3 is found at Genbank Accession Number U74611 (Marsters, et al., Curr. Biol., 1996, 6 (12), 1669-76) which are incorporated herein by reference.

UPAP0020-001

PATENT

Sequence information for AIR is found at Genbank Accession Number U78029 which is incorporated herein by reference.

Sequence information for LARD is found at Genbank Accession Number U94512 (Screaton, et al., Proc. Natl. Acad. Sci. USA, 1997, 94(9), 4615-19) which are incorporated
5 herein by reference.

Sequence information for NGRF is found at Genbank Accession Number M14764 (Johnson, et al., Cell, 1986, 47(4), 545-554) which are incorporated herein by reference.

Sequence information for DR4(TRAIL) is found at Genbank Accession Number U90875 (Pan, et al., Science, 1997, 276(5309), 111-113) which are incorporated herein by
10 reference.

Sequence information for DR5 is found at Genbank Accession Number AF012535 (Sheridan, et al. , Science, 1997, 277(5327), 818-821) which are incorporated herein by reference.

Sequence information for KILLER is found at Genbank Accession Number
15 AF022386 (Wu, et al., Nat. Genet. 17 (2), 141-143 (1997)) which are incorporated herein by reference.

Sequence information for TRAIL-R2 is found at Genbank Accession Number AF020501 which is incorporated herein by reference.

Sequence information for TRICK2 is found at Genbank Accession Number
20 AF018657.

Sequence information for DR6 is found at Genbank Accession Number AF068868 which is incorporated herein by reference.

UPAP0020-001

PATENT

Sequence information for ICE is found at Genbank Accession Numbers U13697, U13698 and U13699 (Alnemri, E.S., et al., J. Biol. Chem. 270 (9), 4312-4317 (1995)) which are incorporated herein by reference.

Sequence information for VLA-1 is found at Genbank Accession Number X17033
5 (Takada., et al., J. Biol. Chem. 109 (1), 397-407 (1989)) which are incorporated herein by reference.

Sequence information for CD86 (B7.2) is found at Genbank Accession Number U04343 (Azuma, et al., Nature. 366 (6450), 76 (1993)) which are incorporated herein by reference.

10

UPAP0020-001

PATENT

Table 1

	Picornavirus Family	
5	Genera: Rhinoviruses: (Medical) responsible for - 50% cases of the common cold. 5 Etheroviruses: (Medical) includes polioviruses, coxsackieviruses, echoviruses, and human enteroviruses such as hepatitis A virus. Aphoviruses: (Veterinary) these are the foot and mouth disease viruses. Target antigens: VP1, VP2, VP3, VP4, VPG	
10	Calcivirus Family	Genera: Norwalk Group of Viruses: (Medical) these viruses are an important causative agent of epidemic gastroenteritis.
	Togavirus Family	
15		Genera: Alphaviruses: (Medical and Veterinary) examples include Senilis viruses, RossRiver virus and Eastern & Western Equine encephalitis. Reovirug: (Medical) Rubella virus.
	Flariviridue Family	
20		Examples include: (Medical) dengue, yellow fever, Japanese encephalitis, St. Louis encephalitis and tick borne encephalitis viruses. West Nile virus (Genbank NC001563, AF533540, AF404757, AF404756, AF404755, AF404754, AF404753, AF481864, M12294, AF317203, AF196835, AF260969, AF260968, AF260967, AF206518 and AF202541)
25	Representative Target antigens:	E NS5 C
30	Hepatitis C Virus: (Medical) these viruses are not placed in a family yet but are believed to be either a togavirus or a flavivirus. Most similarity is with togavirus family.	
	Coronavirus Family: (Medical and Veterinary)	
35		Infectious bronchitis virus (poultry) Porcine transmissible gastroenteric virus (pig) Porcine hemagglutinating encephalomyelitis virus (pig) Feline infectious peritonitis virus (cats)

UPAP0020-001

PATENT

Feline enteric coronavirus (cat)
 Canine coronavirus (dog)
 SARS associated coronavirus
 The human respiratory coronaviruses cause ~40 cases of common cold.
 EX. 224E, OC43
 Note - coronaviruses may cause non-A, B or C hepatitis

Target antigens:

E1 - also called M or matrix protein
 E2 - also called S or Spike protein
 E3 - also called BE or hemagglutinin-esterase
 glycoprotein (not present in all coronaviruses)
 N - nucleocapsid

Rhabdovirus Family

Genera: Vesiliovirus
 Lyssavirus: (medical and veterinary)
 rabies

Target antigen: G protein
 N protein

Filoviridae Family: (Medical)

Hemorrhagic fever viruses such as Marburg and Ebola virus

Paramyxovirus Family:

Genera: Paramyxovirus: (Medical and Veterinary)
 Mumps virus, New Castle disease virus (important
 pathogen in chickens)
 Morbillivirus: (Medical and Veterinary)
 Measles, canine distemper
 Pneumovirus: (Medical and Veterinary)
 Respiratory syncytial virus

Orthomyxovirus Family (Medical)

The Influenza virus

Bunyavirus Family

Genera: Bunyavirus: (Medical) California encephalitis, LA

Crosse

Phlebovirus: (Medical) Rift Valley Fever
 Hantavirus: Puumala is a hemorrhagic fever virus
 Nairovirus (Veterinary) Nairobi sheep disease
 Also many unassigned bunyaviruses

UPAP0020-001

PATENT

Arenavirus Family (Medical)

LCM, Lassa fever virus

Reovirus Family

Genera:

Reovirus: a possible human pathogen
 Rotavirus: acute gastroenteritis in children
 Orbiviruses: (Medical and Veterinary)
 Colorado Tick fever, Lebombo (humans) equine
 encephalosis, blue tongue

Retrovirus Family

Sub-Family:

Oncorivirinal: (Veterinary) (Medical) feline leukemia
 virus, HTLV I and HTLV II
 Lentivirinal: (Medical and Veterinary) HIV, feline
 immunodeficiency virus, equine infections, anemia

Spumavirinal

Papovavirus Family

Sub-Family:

Polyomaviruses: (Medical) BKU and JCU viruses

Sub-Family:

Papillomavirus: (Medical) many viral types associated
 with cancers or malignant progression of papilloma.

Adenovirus (Medical)

EX AD7, ARD., O.B. - cause respiratory disease - some
 adenoviruses such as 275 cause enteritis

Parvovirus Family (Veterinary)

Feline parvovirus: causes feline enteritis
 Feline panleucopeniavirus
 Canine parvovirus
 Porcine parvovirus

Herpesvirus Family

Sub-Family: alphaherpesviridae

Genera:

Simplexvirus (Medical)
 HSV I (Genbank X14112, NC001806), HSV II

Varicellovirinis: (Medical Veterinary) pseudorabies -
 varicella zoster

Sub-Family -

Genera:

betaherpesviridae
 Cytomegalovirus (Medical)
 HCMV
 Muromegalovirus

UPAP0020-001

PATENT

	Sub-Family:	Gammaherpesviridae
	Genera:	Lymphocryptovirus (Medical)
		EBV - (Burkitts lympho)
		Rhadinovirus
5	Poxvirus Family	
	Sub-Family:	Chordopoxviridae (Medical - Veterinary)
	Genera:	Variola. (Smallpox)
		Vaccinia (Cowpox)
		Parapoxivirus - Veterinary
10		Auipoxvirus - Veterinary
		Capripoxvirus
		Leporipoxvirus
		Suipoxvirus
	Sub-Family:	Entomopoxviridae
15	Hepadnavirus Family	
		Hepatitis B virus
	Unclassified	Hepatitis delta virus

UPAP0020-001

PATENT

Table 2

Bacterial pathogens

5 Pathogenic gram-positive cocci include: pneumococcal; staphylococcal; and streptococcal. Pathogenic gram-negative cocci include: meningococcal; and gonococcal.

10 Pathogenic enteric gram-negative bacilli include: enterobacteriaceae; pseudomonas, acinetobacteria and eikenella, melioidosis; salmonella; shigellosis; hemophilus; chancroid; brucellosis; tularemia; yersinia (pasteurella); streptobacillus mortiliformis and spirillum; listeria monocytogenes; erysipelotheix rhusiopathiae; diphtheria, cholera, anthrax; donovanosis (granuloma inguinale); and bartonellosis.

15 Pathogenic anaerobic bacteria include: tetanus; botulism; other clostridia; tuberculosis; leprosy; and other mycobacteria. Pathogenic spirochetal diseases include: syphilis; - treponematoses: yaws, pinta and endemic syphilis; and leptospirosis.

20 Other infections caused by higher pathogen bacteria and pathogenic fungi include: actinomycosis; nocardiosis; cryptococcosis, blastomycosis, histoplasmosis and coccidioidomycosis; candidiasis, aspergillosis, and mucormycosis; sporotrichosis; paracoccidioidomycosis, petriellidiosis, torulopsosis, mycetoma, and chromomycosis; and dermatophytosis.

25 Rickettsial infections include rickettsial and rickettsioses.

30 Examples of mycoplasma and chlamydial infections include: mycoplasma pneumoniae; lymphogranuloma venereum; psittacosis; and perinatal chlamydial infections.

Pathogenic eukaryotes

35 Pathogenic protozoans and helminths and infections thereby include: amebiasis; malaria; leishmaniasis; trypanosomiasis; toxoplasmosis; pneumocystis carinii; babesiosis; giardiasis; trichinosis; filariasis; schistosomiasis; nematodes; trematodes or flukes; and cestode (tapeworm) infections.

UPAP0020-001

PATENT

Claims

1. An isolated nucleic acid molecule comprising a nucleic acid sequence that encodes a non-immunogenic fusion protein that comprises a non-IL-15 signal peptide linked to IL-15 protein or a functional fragment thereof.
- 5 2. The isolated nucleic acid molecule of claim 1 wherein the fusion protein consists of a non-IL-15 signal peptide linked to IL-15 protein or a functional fragment thereof.
3. The isolated nucleic acid molecule of claim 1-2 wherein said IL-15 protein or a functional
10 fragment thereof is IL-15 protein free of IL-15 signal peptide or a functional fragment of IL-15 protein free of IL-15 signal peptide.
4. The isolated nucleic acid molecule of claim 1-3 wherein the nucleic acid sequence that encodes the IL-15 protein or functional fragment thereof is free of IL-15 Kozak region and/or
15 IL-15 5' untranslated region and/or IL-15 3' untranslated region.
5. The isolated nucleic acid molecule of claim 1-4 further comprising a nucleotide sequence that encodes CD40L or a functional fragment thereof.
- 20 6. An isolated nucleic acid molecule comprising a nucleic acid sequence that encodes a fusion protein that comprises a non-IL-15 signal peptide linked to IL-15 protein or a functional fragment thereof and a nucleotide sequence that encodes CD40L or a functional fragment thereof.

UPAP0020-001

PATENT

7. The isolated nucleic acid molecule of claim 6 wherein said fusion protein consists of a non-IL-15 signal peptide linked to IL-15 protein or a functional fragment thereof.

5 8. The isolated nucleic acid molecule of claim 6-7 wherein said IL-15 protein or a functional fragment thereof is IL-15 protein free of IL-15 signal peptide or a functional fragment of IL-15 protein free of IL-15 signal peptide.

9. The isolated nucleic acid molecule of claim 6-8 wherein the nucleic acid sequence that
10 encodes the IL-15 protein or functional fragment thereof is free of IL-15 Kozak region and/or IL-15 5' untranslated region and/or IL-15 3' untranslated region.

10. The isolated nucleic acid molecule of claim 1-9 further comprising a nucleic acid sequence that encodes an immunogen.

15

11. An isolated nucleic acid molecule comprising a nucleic acid sequence that encodes a fusion protein that comprises a non-IL-15 signal peptide linked to IL-15 protein or a functional fragment thereof and a nucleotide sequence that encodes an immunogen.

20 12. The isolated nucleic acid molecule of claim 1 wherein said fusion protein consists of a non-IL-15 signal peptide linked to IL-15 protein or a functional fragment thereof.

UPAP0020-001

PATENT

13. The isolated nucleic acid molecule of claim 11-12 wherein said IL-15 protein or a functional fragment thereof is IL-15 protein free of IL-15 signal peptide or a functional fragment of IL-15 protein free of IL-15 signal peptide.

5 14. The isolated nucleic acid molecule of claim 11-13 wherein the nucleic acid sequence that encodes the IL-15 protein or functional fragment thereof is free of IL-15 Kozak region and/or IL-15 5' untranslated region and/or IL-15 3' untranslated region

10 15. The isolated nucleic acid molecule of claim 10-14 wherein said immunogen is a pathogen antigen, a cancer-associated antigen or an antigen linked to cells associated with autoimmune diseases.

16. The isolated nucleic acid molecule of claim 15 wherein said immunogen is a pathogen antigen.

15

17. The isolated nucleic acid molecule of claim 16 wherein said pathogen antigen is from a pathogen selected from the group consisting of HIV, HSV, HCV, and WNV.

18. The isolated nucleic acid molecule of claims 1-17 wherein said isolated nucleic acid
20 molecule is a plasmid.

19. The nucleic acid molecule of claims 1-17 incorporated into a viral vector.

UPAP0020-001

PATENT

20. A composition comprising a nucleic acid molecule of claim 1-17 and a nucleic acid molecule that comprises a nucleic acid sequence that encodes an immunogen.

21. The composition of claim 20 wherein a nucleic acid molecule further comprises a
5 nucleotide sequence that encodes CD40L.

22. The composition of claim 20 further comprising a nucleic acid molecule that comprises a nucleotide sequence that encodes CD40L.

10 23. The composition of claim 20 wherein said immunogen is a pathogen antigen, a cancer-associated antigen or an antigen linked to cells associated with autoimmune diseases.

24. The composition of claim 23 wherein said immunogen is a pathogen antigen.

15 25. The composition of claim 24 wherein said pathogen antigen is from a pathogen selected from the group consisting of HIV, HSV, HCV, and WNV.

20 26. A composition comprising a nucleic acid molecule that comprises a nucleic acid sequence that encodes a fusion protein that comprises a non-IL-15 signal peptide linked to IL-15 protein or a functional fragment thereof and a nucleic acid molecule that comprises a nucleotide sequence that encodes CD40L or a functional fragment thereof.

UPAP0020-001

PATENT

27. The composition of claim 26 wherein said fusion protein consists of a non-IL-15 signal peptide linked to IL-15 protein or a functional fragment thereof.

28. The composition of claims 26-27 wherein said IL-15 protein or a functional fragment thereof is IL-15 protein free of IL-15 signal peptide or a functional fragment of IL-15 protein free of IL-15 signal peptide.

29. The composition of claims 26-28 wherein the nucleic acid sequence that encodes the IL-15 protein or functional fragment thereof is free of IL-15 Kozak region and/or IL-15 5' untranslated region and/or IL-15 3' untranslated region.

30. The composition of claims 26-29 wherein a nucleic acid molecule further comprises a nucleotide sequence that encodes an immunogen.

31. The composition of claims 26-29 further comprising a nucleic acid molecule that comprises a nucleotide sequence that encodes an immunogen.

32. The composition of claims 30-31 wherein said immunogen is a pathogen antigen, a cancer-associated antigen or an antigen linked to cells associated with autoimmune diseases.

33. The composition of claim 32 wherein said immunogen is a pathogen antigen.

UPAP0020-001

PATENT

34. The composition of claim 33 wherein said pathogen antigen is from a pathogen selected from the group consisting of HIV, HSV, HCV, and WNV.

35. The composition of claims 20-34 wherein said nucleic acid molecules are plasmids.

5

36. An injectable pharmaceutical composition comprising the nucleic acid molecules of claims 51-69 or the composition of claims 20-34.

37. A method of modulating an immune response in an individual comprising administering to said individual a nucleic acid molecule of claims 1-9 or a composition of claims 26-29.

10

38. A recombinant vaccine comprising a nucleic acid sequence that encodes an immunogen and a nucleic acid sequence that encodes a fusion protein that comprises a non-IL-15 signal peptide linked to IL-15 protein or a functional fragment thereof.

15

39. The recombinant vaccine of claim 38 wherein the non-immunogenic fusion protein that consists of a non-IL-15 signal peptide linked to IL-15 protein or a functional fragment thereof.

40. The recombinant vaccine of claim 38-40 wherein IL-15 protein or functional fragment thereof is IL-15 protein free of IL-15 signal peptide or a functional fragment of IL-15 protein free of IL-15 signal peptide.

20

UPAP0020-001

PATENT

41. The recombinant vaccine of claims 38-41 wherein the nucleic acid sequence that encodes the IL-15 protein or functional fragment thereof is free of IL-15 Kozak region and/or IL-15 5' untranslated region and/or IL-15 3' untranslated region.

5 42. The recombinant vaccine of claims 38-42 further comprising a nucleotide sequence that encodes CD40L.

43. The recombinant vaccine of claims 38-43 wherein the fusion protein is non-immunogenic.

10 44. The recombinant vaccine of claims 38-43 wherein said immunogen is a pathogen antigen, a cancer-associated antigen or an antigen linked to cells associated with autoimmune diseases.

15 45. The recombinant vaccine of claim 44 wherein said immunogen is a pathogen antigen.

46. The recombinant vaccine of claim 45 wherein said pathogen antigen from a pathogen selected from the group consisting of HIV, HSV, HCV, and WNV.

20 47. The recombinant vaccine of claims 38-46 wherein said recombinant vaccine is a recombinant vaccinia vaccine.

UPAP0020-001

PATENT

48. A method of inducing an immune response in an individual against an immunogen comprising administering to said individual a nucleic acid molecule of claims 10-17, or a composition of claims 20-25 or 30-34, or a recombinant vaccine of claims 38-47.

5 49. A live attenuated pathogen comprising a nucleotide sequence that encodes a fusion protein comprising a non-IL-15 signal peptide linked to IL-15 protein or a functional fragment thereof.

10 50. The live attenuated pathogen of claim 49 wherein the fusion protein consists of a non-IL-15 signal peptide linked to IL-15 protein or a functional fragment thereof.

15 51. The live attenuated pathogen of claims 49-50 wherein IL-15 protein or a functional fragment thereof is IL-15 protein free of IL-15 signal peptide or a functional fragment of IL-15 protein free of IL-15 signal peptide.

52. The live attenuated pathogen of claims 49-51 wherein the nucleic acid sequence that encodes the IL-15 protein or functional fragment thereof is free of IL-15 Kozak region and/or IL-15 5' untranslated region and/or IL-15 3' untranslated region.

20 53. The live attenuated pathogen of claims 49-52 further comprising a nucleotide sequence that encodes CD40L.

UPAP0020-G01

PATENT

54. A method of immunizing an individual against a pathogen comprising administering to said individual the live attenuated pathogen of claims 49-53.

55. A non-immunogenic fusion protein that comprises a non-IL-15 signal sequence linked to
5 an IL-15 protein sequence.

56. The non-immunogenic fusion protein of claim 55 consisting of a non-IL-15 signal sequence linked to an IL-15 protein sequence.

10 57. The non-immunogenic fusion protein of claims 55-56 wherein the IL-15 protein sequence is free of IL-15 signal sequence.

58. An isolated nucleic acid molecule that comprises a nucleic acid sequence that encodes IL-15 protein and a nucleotide sequence that encodes CD40L protein.

15 59. The nucleic acid molecule of claim 58 further comprising a nucleic acid sequence that encodes an immunogen.

20 60. The nucleic acid molecule of claims 58-59 wherein the nucleic acid molecule is a plasmid.

61. The nucleic acid molecule of claims 58-59 wherein the nucleic acid molecule is incorporated in a viral vector.

UPAP0020-001

PATENT

62. A composition that comprises a first nucleic acid molecule that is a nucleic acid of claims 58-59 and a second nucleic acid molecule that comprises a nucleotide sequence that encodes an immunogen.

5

63. A composition that comprises a first nucleic acid molecule comprising a nucleic acid sequence that encodes IL-15 protein and a second isolated nucleic acid molecule comprising a nucleotide sequence that encodes CD40L protein.

10 64. The composition of claim 63 wherein the said first isolated nucleic acid molecule and/or said second nucleic acid molecule further comprises a nucleic acid sequence that encodes an immunogen.

15 65. The composition of claims 59, 62 or 64 wherein said immunogen is a pathogen antigen, a cancer-associated antigen or an antigen linked to cells associated with autoimmune diseases.

66. The composition of claim 65 wherein said immunogen is a pathogen antigen.

20 67. The composition of claim 66 wherein said immunogen is a pathogen antigen from a pathogen selected from the group consisting of HIV, HSV, HCV, and WNV.

68. The composition of claims 62-67 wherein the isolated nucleic acid molecules are plasmids.

UPAP0020-001

PATENT

69. A method of modulating an immune response in an individual comprising administering .
to said individual a composition of claims 58 or 63.

70. A method of inducing an immune response in an individual against an immunogen
5 comprising administering to said individual a composition of claims 59, 62 or 64-67.

71. A live attenuated pathogen comprising a nucleotide sequence that encodes IL-15 and a
nucleotide sequence that encodes CD40L.

10 72. A method of immunizing an individual against a pathogen comprising administering to
said individual the live attenuated pathogen of claim 71.

UPAP0020-001

PATENT

ABSTRACT

Fusion proteins and nucleic acid molecules encoding fusion proteins are disclosed. The fusion proteins comprise non-IL-15 signal peptide linked to IL-15 protein sequences. Vectors comprising such nucleic acid molecules; and to host cells comprising such vectors
5 are disclosed as well as methods of using such nucleic acid molecules alone or in combination with nucleic acid sequences encoding immunogens and/or CD40 ligand, which are part of the nucleic acid molecules and/or part of a different nucleic acid molecule. Recombinant vaccines and live attenuated pathogens encoding fusion proteins, and methods of using the same, are disclosed. The immunomodulatory effect following delivery of IL-15
10 and a CD40L, with or without immunogens, is disclosed as are various nucleic acid molecules and compositions thereof used for delivering such proteins and methods of using such compositions.




Figure 1

60478210.061303




Figure 2




Figure 3A




Figure 3B




Figure 3C




Figure 3D




Figure 4




Figure 5

60478210.061303




Figure 6






Figure 7

A



B



C




Figure 8




Figure 9

60478210 .06130W

Strategy for Increasing Expression of IL-15 through Optimization of IL-15 DNA Constructs for Immunization

- ❖ Primers are designed to amplify IL-15 from start of signal peptide, thus upstream inhibitory AUGs are not present in the final IL-15 message.
- ❖ Primers are designed to include a strong KOZAK context (GCCGCCACC).
- ❖ Removal of the C-terminus negative regulatory element using PCR antisense primer design

Primer Name	Sense/Antisense	Sequence 5' to 3'
Human IL-15 (LSP)	sense	GCCCCCGTCGACGCCGCCACCATGAGAAATTCGAAACCACATTGAG
	antisense	ATCGGGCTCGAGTCAAGAAGTGTGATGAACATTTGG
Macaque IL-15 (LSP)	sense	GCCCCCGTCGACGCCGCCACCATGAGAAATTCGAAACCACATTGAG
	antisense	ATCGGGCTCGAGTCAAGAAGTGTGATGAACATTTGG
Human IL-15 (SSP)	sense	GCCCCCGGTACC GCCGCCACCATGGTATTGGGAACCATA
	antisense	ATCGGGGGA TCCTCAAGAAGTGTGATGAACAT
Legend: Restriction Site, KOZAK, START, STOP CODON		

Figure 10

60478210, 061106

Strategy for Increasing Expression of IL-15 through Replacement of 48 amino acid Signal Peptide (LSP) with IgE leader

- ❖ Sense primers are designed to start after 48 aa ISP while antisense primer amplifies from stop site.
- ❖ Primers are designed to include a strong KOZAK context (GCCGCCACC).
- ❖ Sense primer is designed to contain the sequence for IgE leader sequence plus a ATG start site.

Primer Name	Sense/Antisense	Sequence 5' to 3'
Human IL-15-IgE	sense	GCCCCCGAATTC GCCGCCACCATGGATTGGACTTGGATCITATTTT
	antisense	AGTTGCTGCTGCTACTAGAGTTCATTCTAACTGGTGAATGTAATAAGT
		ATCGGGCTCGAG TCAAGAAGTGTGATGAACATTGG
Macaque IL-15-IgE	sense	GCCCCCGAATTC GCCGCCACCATGGATTGGACTTGGATCITATTTT
	antisense	AGTTGCTGCTGCTACTAGAGTTCATTCTAACTGGTGAATGTAATAAGT
		ATCGGGCTCGAG TCAAGAAGTGTGATGAACATTGG

Legend: Restriction Site, KOZAK, START, STOP CODON

Figure 11






Figure 12

60478210 .061303

Figure 13



A**B**

Figure 14

Immunization Schedule

Immunization Groups:

Naïve


Vector Control

HIV-1 Gag

HIV-1 Gag/ IL15 constructs




*Combinations of 100µg IL15 Constructs, 50µg GAG,
Each injection, intramuscular*



60478210 . 061303

Figure 15

Restimulation of antigen-specific IFN- γ production 5 Weeks Following
the 3rd immunization of HIV-1 Gag in Balb/C mice
Effect of IL-15 Constructs




60478210.061303

An Engineered IL-15 Plasmid Vaccine

(Kozak, AUG's removed, UTR's removed & other-30-50x better expression)

Enhances CTL Response in Vivo

Mice were immunized with HIV-1 gag expressing DNA



Grabstein et al., (1994) Science 264:965-968, Bamford et al., (1996) PNAS 93:2897-2902,
Bamford et al., (1998) J. Immunol 160:4418-4426, Kozak et al., (1991) J. Cell Biol. 115:887-903.

Figure 16

60476210.06130W

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.